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1. Introduction
This report describes the results of the 24th 
proficiency test organised by the Technical 
University of Denmark, National Food Institute 
(DTU-FOOD) as the EU Reference Laboratory 
for Antimicrobial Resistance (EURL-AR). This 
proficiency test focuses on antimicrobial 
susceptibility testing (AST) of enterococci, 
staphylococci and Escherichia coli. It is the 11th 
External Quality Assurance System (EQAS) 
conducted for AST of these microorganisms. 
The aim of this EQAS is to: i) monitor the 
quality of AST results produced by National 
Reference Laboratories (NRL-AR), ii) identify 
laboratories which may need assistance to 
improve their performance in AST, and iii) 
determine possible topics for future research 
and collaboration. 
When reading this report, please consider: 
1) Expected results were generated by
performing Minimum Inhibitory Concentration
(MIC) determination on two occasions at DTU-
FOOD. These results were verified by the
United States Food and Drug Administration
(FDA), Centre for Veterinary Medicine. Finally,
MIC determination was performed at DTU-
FOOD after preparation of the agar stab
cultures to be shipped to participants to confirm
that the vials contained the correct strains with
the expected MIC values.
2) The evaluation is based on interpretation of
MIC values obtained in agreement with i) the
method reported in Decision 2013/652/EU, for
testing of E. coli and enterococci; and ii) the
most recent recommendations from EFSA, for
testing of staphylococci (EFSA, 2012).
Participants were requested to apply the same
method used when generating AST results to
be reported to EFSA. This request was made to
ensure compliance with the main objective of
this EQAS “to assess and improve the
comparability of antimicrobial susceptibility data
reported to EFSA by the different NRLs”, as 
stated in the protocol (Appendix 4). 
3) Only results obtained by MIC determination
methods were allowed in this EQAS to comply
with Decision 2013/652/EU. Thus, the set-up of
the database for reporting results did not allow
upload of disk diffusion results.
4) Laboratory performance is considered
acceptable if there are < 5% deviations from
expected results, as previously agreed by the
EURL-AR network.
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analysed in a self-evaluation procedure 
performed by individual participants when the 
EQAS results are disclosed. MIC determination 
methods have limitations in reproducibility. 
Thus, on repeated testing, the same 
strain/antimicrobial combination can result in 
two MIC values differing by one-fold dilution. If 
the expected MIC is close to the breakpoint 
value for categorising the strain as susceptible 
or resistant, a one-fold dilution difference may 
result in different interpretations. Since this 
report evaluates the interpretations of MIC 
values, some participants may find their results 
classified as wrong even though the actual MIC 
measured is only one-fold dilution different from 
the expected MIC. In these cases (hereafter 
defined “one-fold dilution issues”), the 
participants should be confident about the good 
quality of their AST performance. At the EURL-
AR, we strive to select test strains with MIC 
values distant from the breakpoints for 
resistance to avoid these ambiguous situations, 
though this is not always feasible for all strains 
and antimicrobial combinations. For this reason, 
the EURL-AR network unanimously established 
in 2008 that, if there are less than 75% correct 
results for a specific strain/antimicrobial 
combination, these results may be subtracted 
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from the evaluation report after a case by case 
evaluation to be detailed in the report. 
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRLs who 
meet yearly at the EURL-AR workshop. 
All conclusions presented in this report are 
publicly available. However, participating 
laboratories are identified by codes and each 
code is known only to the corresponding 
laboratory. The full list of laboratory codes is 
confidential information known only by relevant 
representatives of the EURL-AR and the EU 
Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
2. Materials and Methods
2.1 Participants in EQAS 2018 
A pre-notification to announce the EQAS 2018 
on AST of enterococci, staphylococci and E. 
coli (Appendix 1) was sent by e-mail on the 16th 
April 2018 to the designated NRL-AR in the 
network and to eleven additional laboratories in 
Denmark, Iceland, Israel, the Netherlands, 
North Macedonia, Norway, Serbia, Spain, 
Switzerland, Turkey and United Kingdom invited 
to participate based on participation to previous 
EQAS iterations and/or affiliation to the EU 
network. 
Participating laboratories represented all 28 EU 
Member States (MS) and four non-MS (Iceland, 
North Macedonia, Norway, and Switzerland; 
Appendix 2 and Figure 1). Only one set of data 
per MS is included in this report. 
2.2 Strains  
The eight enterococci, eight staphylococci and 
eight E. coli included in this EQAS were 
selected among the DTU-FOOD strain 
collection based on available MIC data. For 
quality assurance purposes, one strain per 
each bacterial species has been included in all 
Figure 1. Countries colored in red participated to the EURL-AR EQAS on antimicrobial susceptibility testing 
of enterococci, staphylococci and/or Escherichia coli, 2018 
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EQAS iterations performed to date to represent 
an internal control. 
Expected MIC values (Appendix 3) for this 
EQAS were generated by using Sensititre 
panels (Trek Diagnostic Systems) at DTU-
FOOD and further verified by the U.S. FDA. 
Results could not be verified by FDA for: 
ampicillin and teicoplanin (enterococci); colistin, 
ertapenem, meropenem, temocillin, 
trimethoprim and tigecycline (E. coli); and 
cefoxitin, clindamycin, mupirocin, 
sulfamethoxazole, sulfamethoxazole-
trimethoprim, tiamulin and trimethoprim 
(staphylococci). MICs were further determined 
at DTU-FOOD after production of agar stab 
cultures to confirm expected values prior to 
shipment and to ensure homogeneity of the test 
cultures. 
Reference strains Enterococcus faecalis ATCC 
29212, Staphylococcus aureus ATCC 29213 
and E. coli ATCC 25922 were provided to new 
participants with instructions to store and 
maintain them for quality assurance purposes 
and future EQAS trials. The expected quality 
control ranges for the reference strains were 
retrieved from Clinical and Laboratory 
Standards Institute (CLSI) in documents M100-
28th Ed. (2018) (App. 5).  
2.3 Antimicrobials 
The panels of antimicrobials recommended for 
AST in this trial are listed in Table 1. 
These antimicrobials represent those defined 
by the Commission Implementing Decision 
2013/652/EU for E. coli and enterococci, and 
those most recently recommended by EFSA for 
staphylococci. 
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
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2.4 Distribution 
The bacterial strains were dispatched as agar 
stab cultures on 31st May 2018. These bacterial 
cultures were shipped in double pack 
containers (class UN 6.2) as UN3373, biological 
substances category B according to the 
International Air Transport Association (IATA) 
regulations. 
2.5 Procedure 
The participants were recommended to keep 
the agar stab cultures refrigerated until 
performance of AST. Protocols and all relevant 
information were uploaded on the EURL-AR 
website (http://www.eurl-ar.eu) thus being 
available at any time (Appendix 4). Guidelines 
for performing AST were set according to the 
the ISO standard, ISO 20776-1 “Clinical 
laboratory testing and in vitro diagnostic test 
system – Susceptibility testing of infectious 
agents and evaluation of performance of 
antimicrobial susceptibility test devices”. 
Instructions for interpretation of AST results 
adhered to those specified in the Commission 
Implementing Decision 2013/652/EU, and were 
provided in the protocol (Appendix 4b: Tables 1, 
2 and 3).  Participants were invited to 
categorise the strains as resistant or 
susceptible using EUCAST epidemiological cut-
off (ECOFF) values (www.eucast.org). For 
interpretation of the results of the E. coli 2nd 
panel (to be tested when a strain displayed 
resistance to cefotaxime, ceftazidime and/or 
meropenem in the E. coli 1st panel) participants 
were invited to adhere to recommendations by 
EFSA (Appendix 4b). 
The EURL-AR is aware that there are two types 
of criteria for interpretation of MIC results: 
clinical breakpoints and ECOFF values. The 
terms ‘susceptible’, ‘intermediate’ and ‘resistant’ 
should be used for classification made in 
relation to the therapeutic application of 
Table 1. Panels of antimicrobials for antimicrobial susceptibility testing included in this EURL-AR EQAS 2018 component 
Enterococci  Staphylococci  Escherichia coli  1st panel 
Escherichia coli 
2nd panel 
Ampicillin, AMP  Cefoxitin, FOX  Ampicillin, AMP  Cefepime, FEP  
Chloramphenicol, CHL Chloramphenicol, CHL Azithromycin, AZI  Cefotaxime +
clavulanic acid (F/C)  
Ciprofloxacin, CIP  Ciprofloxacin, CIP Cefotaxime, FOT  Cefotaxime, FOT  
Daptomycin, DAP  Clindamycin, CLN Ceftazidime, TAZ  Cefoxitin, FOX 
Erythromycin, ERY  Erythromycin, ERY  Chloramphenicol, CHL Ceftazidime, TAZ  
Gentamicin, GEN Gentamicin, GEN Ciprofloxacin, CIP  Ceftazidime+ 
clavulanic acid (T/C)  
Linezolid, LZD  Linezolid, LZD Colistin, COL Ertapenem, ETP  
Quinupristin-dalfopristin 
(Synercid), SYN  
Mupirocin, MUP Gentamicin, GEN Imipenem, IMI 
Teicoplanin, TEI Quinupristin-dalfopristin (Synercid), 
SYN  
Meropenem, MERO Meropenem, MERO 
Tetracycline, TET  Sulfamethoxazole, SMX  Nalidixic acid, NAL  Temocillin, TRM 
Tigecycline, TGC Sulfamethoxazole+Trimethoprim, SXT  Sulfamethoxazole, SMX  
Vancomycin, VAN Tetracycline, TET  Tetracycline, TET  
Tiamulin, TIA Tigecycline, TGC 
Trimethoprim, TMP Trimethoprim, TMP 
Vancomycin, VAN 
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antimicrobial agents, whereas bacteria should 
be reported as ‘wild-type’ or ‘non-wild-type’ 
when reporting data relative to ECOFF values 
(Schwarz et al., 2010). To simplify the 
interpretation of results, we maintain the terms 
susceptible and resistant throughout this report 
even when referring to wild-type and non-wild-
type strains, respectively. 
All participants were invited to enter the 
obtained results into an electronic record sheet 
at the EURL-AR web-based database designed 
for this trial. Participants were also encouraged 
to complete an evaluation form available on the 
EURL-AR database with the aim to improve 
future EQAS trials. 
The database could be accessed through a 
secured individual login and password.  
The database was closed on 5th October 2018. 
After this date, the participants were invited to 
login again to retrieve an individual database-
generated evaluation report.  
3. Results and Discussion
In this report, results from 28, 25 and 32 
laboratories for enterococci, staphylococci and 
E. coli were evaluated, respectively. The
participants were invited to report MIC values
and categorisation as resistant or susceptible
for each strain/antimicrobial combination. Only
the categorisation was evaluated, whereas the
MIC values were used as supplementary
information.
3.1 Results excluded from the 
report 
The following strain/antimicrobial combinations 
resulted in ≥ 25% deviations from expected 
results: ENT-12.3/CHL, ENT-12.5/DAP, ENT-
12.6/CIP, ST-12.1/CIP, ST-12.2/SMX, ST-
12.3/SYN, EC-12.6/IMI, EC-12.7/GEN and EC-
12.7/IMI. In agreement with the decision by the 
EURL-AR network these results were carefully 
evaluated as reported below. 
Table 2. Strain/antimicrobial combinations yielding 





ENT-12.3/CHL 64/R 21 7
ENT-12.5/DAP4 8/R 4 18 
ENT-12.6/CIP 4/S 8 20
ST-12.1/CIP5 1/S 10 14 
ST-12.3/SYN6 1/S 4 18 
EC-12.6/IMI7 2/R 7 11
EC-12.7/GEN 4/R 48 28
EC-12.7/IMI9 0.5/S 14 16
CHL, chloramphenicol; CIP, ciprofloxacin; DAP, daptomycin; 
GEN, gentamicin; IMI, imipenem; SYN, quinupristin-
dalfopristin. 
1int., interpretation; 2Number of labs with expected MIC and 
interpretation; 3Number of labs with one-step dilution difference 
from expected MIC value (if not otherwise specified) leading to 
interpretation different from expected; 4Six laboratories had > 
one-fold-dilution difference compared to expected MIC; 5One 
laboratory had MIC one-fold dilution different from expected 
value leading to same interpretation as expected. 6One 
laboratory did not upload any result for this strain/antimicrobial 
combination, one laboratory had MIC one-fold dilution different 
from expected value leading to same interpretation as 
expected.and another laboratory had > one-fold-dilution 
difference; 7Three laboratories did not report MIC and/or 
interpretation and 11 laboratories had > one-fold-dilution 
difference compared to expected MIC; 8One participant 
reported MIC=4 mg/L but interpreted it as S; 9One laboratory 
did not report imipenem MIC and one laboratory reported MIC 
as expected (0.5 mg/L) but interpretation as R. Among the 16 
laboratories in disagreement, eight had MIC=1 mg/L, which is 
one-step dilution above expected values and eight had 
MIC=0.25 mg/L, which is one-step dilution below expected 
value.  
All results regarding the strain/antimicrobial 
combinations reported in Table 2 were excluded 
from the report as they mostly represented 
deviations caused by “one-fold dilution issues” 
that cannot be considered representative of the 
ability of the laboratories to perform AST. 
For the strain/antimicrobial combination ST-
12.2/SMX (sulfamethoxazole), it was noticed 
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that 21 (91%) of the 23 participants reporting 
SMX results for ST-12.2 obtained MIC ≤ 64 
(n=18) or ≤ 128 (n=3) (leading to classification 
of the strain as SMX susceptible), which in both 
cases differed more than one-step dilution from 
the expected MIC > 512 (leading to 
classification of the strain as SMX resistant). 
Based on this, further investigations were made 
as follows. First of all, the EQAS preparation 
documents were retrieved and it was indeed 
noted that SMX MIC for this strain was unclear 
as there was growth in all SMX wells which 
however was smaller than the growth of the 
positive control. However, when deciding upon 
expected results, it was considered < 80% 
inhibition compared to the growth of the positive 
control. Furthermore, an analysis of whole 
genome sequence data was performed. The 
strain ST-12.2 had three mutations in the 
dihydropteroate synthase gene leading to 
amino acid changes T59S, V60L and F266L 
compared to the wild-type. The exact 
contribution of different mutations in the 
dihydropteroate synthase gene to 
sulfamethoxazole resistance in S. aureus has 
not been fully elucidated yet. However, these 
mutations usually appear in combination with 
additional mutations in sulfamethoxazole 
resistant strains thus they may not be sufficient 
to confer a resistance phenotype when present 
alone (Hampele et al., 1997; Yun et al., 2012). 
Based on the above, it was decided to revise 
the expected SMX MIC value for ST-12.2 as ≤ 
64/S. 
3.2 Overall performance 
The percentage of results in agreement with 
those expected ranged from 96.3% (strain ST-
12.5) to 100% (strain EC-12.1 and EC-12.5) 
(Table 3). The E. coli trial yielded the highest 
percentage of correct results (99.1%), tightly 
followed by the S. aureus trial (98.7%) and by 
the enterococci trial (98.2%). 
The percentage of deviations from the expected 
results appears to be low (below 2%) and 
stable (Figure 2). The results for the internal E. 
coli and S. aureus control strains were the best 
ever obtained since the beginning of these 
EQAS components in 2008 (Figure 2). The 
results for the Enterococcus sp. reference 
strains were good with a fairly stable level of ca. 
2% deviations since 2013. The list of deviations 
is reported in Appendices 8a, 8b and 8c.  
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3.2.1 Enterococci 
Twenty-eight laboratories (from 24 MS and four 
non-EU countries) approved results for the 
enterococci trial. 
Strain-based analysis 
Deviations ranged from 0.6% (n=2) for ENT-
12.7 to 2.9% (n=9) for ENT-12.8 (Figure 3). For 
ENT-12.1, four (50%) out of eight deviations 
were “one-fold dilution issues” and the 
remaining indicated performance problems. For 
Table 3. Total number (No.) and percentage (%) of antimicrobial susceptibility tests (AST) performed and in agreement with 



















ENT-12.1 333 325 97,6 ST-12.1 406 405 99,8 EC-12.1 672 672 100 
ENT-12.2 307 304 99,0 ST-12.2 431 427 99,1 EC-12.2 448 444 99,1 
ENT-12.3 280 276 98,6 ST-12.3 407 403 99,0 EC-12.3 672 668 99,4 
ENT-12.4 336 329 97,9 ST-12.4 431 426 98,8 EC-12.4 448 443 98,9 
ENT-12.5 308 302 98,1 ST-12.5 429 413 96,3 EC-12.5 672 672 100 
ENT-12.6 304 298 98,0 ST-12.6 430 424 98,6 EC-12.6 631 613 97,1 
ENT-12.7 307 305 99,3 ST-12.7 431 426 98,8 EC-12.7 608 602 99,0 
ENT-12.8 308 299 97,1 ST-12.8 431 428 99,3 EC-12.8 672 666 99,1 
*ENT, enterococci; ST, S. aureus ; EC, Escherichia coli.
Figure 2. Overall deviations (%) from expected results by EQAS iteration. ENT, enterococci; ST, staphylococci; EC, 



















Enterococci Staphylococci Escherichia coli
ENT int ctrl ST int ctrl EC int ctrl
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ENT-12.2, ENT-12.3 and ENT-12.7, all (100%) 
three, four and two deviations, respectively, 
indicated performance problems. For ENT-12.4 
and ENT-12.6, most deviations (57%, four out 
of seven and 67%, four out of six, respectively) 
were related to “one-fold dilution issues”. 
Differently, for ENT-12.5 and ENT-12.8, most 
deviations (83%, five out of six and 78%, seven 
out of nine, respectively) indicated performance 
problems. 
Antimicrobial-based analysis 
No deviations from expected results were 
obtained when testing susceptibility to 
ciprofloxacin, gentamicin and tetracycline 
(Figure 4). The antimicrobials that resulted in 
highest percentages of deviations were 
tigecycline (10.4%), quinupristin-dalfopristin 
(4.6%), and chloramphenicol and daptomycin 
(1.5% each). All (n=23) deviations obtained out 
of 224 reported results for tigecycline indicated 
performance issues. Tigecycline is sensitive to 
light and temperature, and degradation of the 
antimicrobial has been described to happen 
frequently if panels are not handled properly 
(please refer also to the presentation by Dr. 




final.pdf). Furthermore, tigecycline MIC reading 
might be difficult due to occurrence of tiny 
pellets of dubious interpretation (trailing 
growth). 
Laboratories that obtained deviations are 
invited to consult the CLSI document M07-
Ed.11th for detailed guidelines on MIC reading 
when trailing occurs and to ensure that 
procedures for handling panels containing 
tigecycline are correct. Furthermore, 
laboratories are welcome to contact the EURL-
AR if further clarifications are needed. For 
quinupristin-dalfopristin, chloramphenicol and 
daptomycin, all deviations (four out of 109 
reported values, 3/196 and 3/196, respectively) 
were “one-fold dilution issues” thus simply a 
consequence of the limitation in reproducibility 
of the MIC method.  
An overview of obtained and expected results is 
reported in Appendix 7a. 
Laboratory-based analysis 
Eleven laboratories (39%) reported all results in 
agreement with those expected (Figure 5). 
Furthermore, all deviations from seven 
additional laboratories were “one-fold dilution 
issues” thus indicating that 64% of the 
laboratories participating to this EQAS 
component had no technical performance 
issues (Figure 5).  
Lab # 26, 39 and 45 had one deviation each. 
Lab # 26 and 45 reported incorrect tigecycline 
MIC, which might be related to the above 
mentioned challenges in testing MIC for this 
antimicrobial, whereas Lab # 39 reported an 
incorrect teicoplanin MIC. 
Lab # 11, 20 and 22 had three deviations each. 
For Lab # 11 and 20 the deviations could 
indicate issues in erythromycin and tigecycline 
MIC testing, respectively. For Lab # 22, most 
deviations were one-fold dilution issues”, thus 
not related to technical performance issues. 
Lab # 17 had four deviations that could indicate 
issues in tigecycline MIC testing.  
Finally, three laboratories had percentages of 
deviations above the threshold for acceptable 
laboratory performance, which is set at 5 % 
(Figure 5). 
Lab # 41 and 61 had six deviations each, which 
mostly indicated challenges in tigecycline MIC 
testing. Lab # 34 had nine deviations, seven of 
which indicated challenges in tigecycline MIC 
testing whereas the remaining were “one-step 
dilution issues”. 
Deviations from expected results obtained by 
each participant in the enterococci trial are 
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
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reported in Appendix 8a. 
Enterococci species identification 
Participants were requested to identify the 
enterococci species as a mandatory 
component. The test strains were four E. 
faecium (ENT-12.1, ENT-12.4, ENT-12.5 and 
ENT-12.6) and four E. faecalis (ENT-12.2, ENT-
12.3, ENT-12.7 and ENT-12.8). Enterococci 
species identification results were uploaded by 
all participants for a total of 224 results that 
were all (100%) in agreement what those 
expected, indicating excellent performance in 
this EQAS component. 
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
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Figure 3. Deviations (%) from expected interpretation of AST result for each Enterococcus sp. strain, EURL-AR 
EQAS 2018. “True deviation” could indicate a technical performance issue, whereas “one-step dilution” represents a 
limitation in reproducibility of the MIC method and not a technical performance issue (see text for further details). 
Sporadic cases of erroneous interpretation of MIC values obtained as expected are included among “one-step dil.”. 
Figure 4. Deviations (%) from expected interpretation of AST results for each antimicrobial. Enterococci component of 
the EURL-AR EQAS 2018. AMP, ampicillin; CHL, chloramphenicol; CIP, ciprofloxacin; DAP, daptomycin; ERY, 
erythromycin; GEN, gentamicin; LZD, linezolid; SYN, quinupristin/dalfopristin (synercid); TEI, teicoplanin; TET, 
tetracycline; TGC, tigecycline; VAN, vancomycin. “True deviation” could indicate a technical performance issue, 
whereas “one-step dilution” represents a limitation in reproducibility of the MIC method and not a technical 
performance issue (see text for further details). Sporadic cases of erroneous interpretation of MIC values obtained as 
expected are included among “one-step dil.”. 
Figure 5. Deviations (%) by participating laboratory in the enterococci trial, EURL-AR EQAS 2018. The dashed line 
indicates the threshold (5%) for acceptable laboratory performance. “True deviation” could indicate a technical 
performance issue, whereas “one-step dilution” represents a limitation in reproducibility of the MIC method and not a 
technical performance issue (see text for further details). Sporadic cases of erroneous interpretation of MIC values 
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3.2.2 Staphylococci 
Twenty-five laboratories (from 22 MS and three 
non-MS) uploaded results for the staphylococci 
trial. 
Strain-based analysis 
Deviations ranged from 0.2% (n=1) in ST-12.1 
to 3.7% (n=16) in ST-12.5 (Figure 6). In ST-
12.7, most (60%, n=3) deviations were “one-
fold dilution issues”. In ST-12.5, half (50%, n=1 
and n=8, respectively) of the observed 
deviations were “one-fold dilution issues”, 
whereas the remaining could indicate 
performance issues. In ST-12.2, ST-12.3, ST-
12.4 and ST12.8, most deviations (75%, n=3; 
75%, n=3; 60%, n=3; and 67%, n=2, 
respectively) could indicate performance 
issues. Finally, all (100%) deviations observed 
for ST12.1 and ST-12.6 (n=1 and n=6, 
respectively) could indicate performance 
issues. 
Antimicrobial-based analysis 
All (100%) results for linezolid, rifampicin, 
streptomycin and vancomycin were in 
agreement with those expected (Figure 7). 
The antimicrobials that resulted in highest 
percentages of deviations were 
sulfamethoxazole (4.8%), quinupristin-
dalfopristin (2.9%), cefoxitin (2.6%) and 
clindamycin (2.5%) (Figure 7). For 
sulfamethoxazole, all (100%) nine deviations 
indicated performance issues. 
Sulfamethoxazole MIC reading is challenging 
as MIC has to be read at the concentration in 
which there is ≥ 80% reduction in growth 
compared to the positive control, which may 
lead to subjective interpretations. 
For quinupristin-dalfopristin, all (100%) five 
deviations represented “one-fold dilution 
issues”, thus indicating no technical 
performance problems in testing S. aureus 
susceptibility to this antimicrobial. 
For cefoxitin, most (60%, three out of five) 
deviations indicated possible performance 
issues. Despite this, it is interesting to notice 
that all laboratories performed correct 
identification of methicillin-resistant and 
methicillin-susceptible S. aureus (MRSA and 
MSSA, respectively; explained further below in 
the report), which suggests that at least some 
laboratories used methods other than cefoxitin 
MIC determination to establish if strains are 
MRSA or MSSA. 
Also for clindamycin, most (60%, three out of 
five) deviations indicated possible performance 
issues. Clindamycin MIC reading may be 
challenging due to trailing growth. Detailed 
guidelines on clindamycin MIC reading are 
reported in the CLSI document M07-Ed.11th. 
An overview of obtained and expected results is 
reported in Appendix 7b. 
Laboratory-based analysis 
Eleven laboratories (44%) reported all results in 
agreement with those expected (Figure 8). 
Furthermore, all deviations from five additional 
laboratories were “one-fold dilution issues” thus 
indicating that 64% of the laboratories 
participating to this EQAS component had no 
technical performance issues (Figure 8).  
Lab # 11, 12 and 36 had one deviation each, 
respectively, caused by incorrect 
sulfamethoxazole MIC. As explained above, 
sulfamethoxazole MIC reading is challenging as 
MIC has to be read at the concentration in 
which there is ≥ 80% reduction in growth 
compared to the positive control, which is prone 
to subjective interpretations. 
Lab # 17, 40 and 56 had four deviations each. 
For Lab # 17 and 56, only half (50%) of the 
deviations were considered “true deviations” 
and might indicate problems in clindamycin and 
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erythromycin MIC determination for ST-12.5 for 
both laboratories. For Lab # 40, most (75%) 
deviations could indicate problems in fusidic 
acid and sulfamethoxazole MIC determination.  
Lab # 34 and 45 had six deviations each. In 
each laboratory, all but one deviation might 
indicate performance issues either in 
sulfamethoxazole MIC reading for Lab # 45 or 
with various strain/antimicrobial combinations 
for Lab # 34. 
Finally, Lab # 39 had 10% deviations, which is 
above the threshold for acceptable laboratory 
performance (5 %) (Figure 8). True deviations 
were observed for four strains and for six 
antimicrobials, thus indicating a general issue 
rather than problems in defining MIC for specific 
challenging antimicrobials. 
Deviations from expected results obtained by 
each participant in the staphylococci trial are 
reported in Appendix 8b. 
Methicillin-resistant S. aureus 
Participants were requested to identify the 
presence/absence of methicillin resistance as a 
mandatory component. The test strains 
included three methicillin-resistant S. aureus 
(MRSA; ST-12.1, ST-12.3 and ST-12.8) and 
five methicillin-susceptible S. aureus (MSSA; 
ST-12.2, ST-12.4, ST-12.5, ST-12.6 and ST-
12.7). All participants submitted MRSA/MSSA 
results. All 200 results were in agreement with 
those expected. 
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Figure 6. Deviations (%) from expected interpretation of AST results for each Staphylococcus aureus strain, EURL-
AR EQAS 2018. “True deviation” could indicate a technical performance issue, whereas “one-step dilution” represents 
a limitation in reproducibility of the MIC method and not a technical performance issue (see text for further details). 
Sporadic cases of erroneous interpretation of MIC values obtained as expected are included among “one-step dil.”. 
Figure 7. Deviations (%) from expected interpretation of AST results for each antimicrobial. Staphylococcus aureus 
component of the EURL-AR EQAS 2018. FOX, cefoxitin; CHL, chloramphenicol; CIP, ciprofloxacin; CLN, clindamycin; 
ERY, erythromycin; FUS, fusidic acid; GEN, gentamicin; KAN, kanamycin; LZD, linezolid; MUP, mupirocin; SYN, 
quinupristin/dalfopristin (synercid); RIF, rifampicin; SMX, sulfamethoxazole; TET, tetracycline; TIA, tiamulin; TMP, 
trimethoprim; VAN, vancomycin.  “True deviation” could indicate a technical performance issue, whereas “one-step 
dilution” represents a limitation in reproducibility of the MIC method and not a technical performance issue (see text 
for further details). Sporadic cases of erroneous interpretation of MIC values obtained as expected are included 
among “one-step dil.”. 
Figure 8. Deviations (%) by participating laboratory in the staphylococci trial, EURL-AR EQAS 2018. The dotted line 
indicates the threshold for acceptable laboratory performance. “True deviation” could indicate a technical 
performance issue, whereas “one-step dilution” represents a limitation in reproducibility of the MIC method and not a 
technical performance issue (see text for further details). Sporadic cases of erroneous interpretation of MIC values 
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3.2.3 Escherichia coli  
Thirty-two laboratories (from 28 MS and four 
non-MS) uploaded results for the E. coli trial. 
Strain-based analysis 
Deviations ranged from 0% for EC-12.1 and 
EC-12.5 to 2.8% (n=18) for EC-12.6 (Figure 9).  
For EC-12.2, all four deviations indicated 
performance problem. For EC-12.3, two out of 
four (50%) deviations were “one-fold dilution 
issues” and the remaining could indicate 
performance problems. For EC-12.4, three 
(60%), out of five deviations were “one-fold 
dilution issues” and the remaining could 
indicate performance problems. For EC-12.6, 
eleven (61%) out of 18 deviations were “one-
fold dilution issues” (n=10) or different 
interpretation of MIC value obtained as 
expected (n=1), and the remaining deviations 
could indicate performance problems. For EC-
12.7, three (50%) of six deviations were “one-
fold dilution issues” and the remaining 
deviations indicated performance problems. For 
EC-12.8, five (83%) out of six deviations were 
“one-fold dilution issues” and the remaining 
deviation indicated a performance problem. 
Antimicrobial-based analysis 
No deviations from expected results were 
obtained when testing susceptibility to 
ampicillin, cefepime, gentamicin, imipenem, 
tetracycline and trimethoprim (Figure 10). The 
antimicrobials that resulted in highest 
percentages of deviations were cefoxitin 
(4.2%), meropenem (2.2%), and azithromycin, 
colisitin and tigecycline (1.5% deviations each) 
(Figure 10). For cefoxitin, eight deviations were 
observed out of 190 uploaded results, and all 
deviations were “one-fold dilution issues”. For 
meropenem, ten deviations were observed out 
of 447 uploaded results. Three (30%) of such 
deviations were “one-fold dilution issues” 
whereas the remaining 70% could indicate 
performance issues. For azithromycin, four 
deviations were observed out of 256 uploaded 
results and most (n=3; 75%) of these deviations 
were “one-fold dilution issues”. For colistin, all 
(n=4, 100%) observed deviations out of 254 
uploaded results were “one-fold dilution issues”. 
For tigecycline, four deviations were observed 
out of 256 uploaded results and half (n=2; 50%) 
of these deviations were “one-fold dilution 
issues”, whereas the remaining deviations 
could indicate performance issues. 
An overview of obtained and expected results is 
reported in Appendix 7c.  
Laboratory-based analysis 
All laboratories (100%) performed within the 
threshold for acceptable laboratory 
performance (≤5%), which represents an 
extremely positive outcome of the E. coli 
component of the EURL-AR EQAS 2018. 
Eighteen laboratories (56.2%) reported all 
results in agreement with those expected and 
(Figure 11). 
Four laboratories (12.5%) had 0.6% deviation 
each representing one deviation per laboratory. 
These deviations were “one-fold dilution issues” 
(n=3) or different interpretation of MIC value 
obtained as expected (n=1, likely indicating an 
inaccuracy when uploading results to the 
database), thus no technical performance 
issues were identified also for Lab # 18, 36, 39 
and 42. 
Two laboratories (6.3%) had 1.3% deviations, 
corresponding to two deviations each. In one 
case (Lab # 6), both deviations were “one-fold 
dilution issues”, so also for this laboratory there 
were no performance issues. In the second 
case (Lab # 23), one deviation was a “one-fold 
dilution issue”, and the remaining one could 
indicate a performance issue. 
Two laboratories (6.3%) had 1.9% deviations, 
corresponding to three deviations each. In one 
case (Lab # 22), two deviations were “one-fold 
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dilution issues” (n=2) or different interpretation 
of MIC value obtained as expected (n=1, likely 
indicating an inaccuracy when uploading results 
to the database), thus also for this laboratory 
there were no technical performance issues. In 
the second case (Lab # 40), one deviation was 
a “one-fold dilution issue”, and the remaining 
two represented true deviations which could 
indicate a performance issue. 
Three laboratories (9.3%) had 2.6% deviations 
corresponding to four deviations each. In Lab # 
4, 33 and 45, 25% (n=1), 50% (n=2) and 100% 
(n=4) of deviations were “one-fold dilution 
issues”, respectively, whereas the remaining 
deviations might indicate a performance issue. 
Two laboratories (6.3%) had 3.3% deviations 
corresponding to five deviations each. In Lab # 
11 and 26, 40% (n=2) and 20% (n=1) of 
deviations were “one-fold dilution issues”, 
respectively, whereas the remaining deviations 
might indicate a performance issue. 
Finally one laboratory (3.1%; Lab # 61) had 
4.8% deviations corresponding to seven results 
deviating from those expected. Three of these 
deviations (43%) were “one-fold dilution 
issues”, whereas the remaining deviations 
might indicate a performance issue. 
Deviations from expected results obtained by 
each participant in the E. coli trial are reported 
in Appendix 8c. 
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Figure 9. Deviations (%) from expected interpretation of AST results for each Escherichia coli strain, EURL-AR EQAS 2018. 
“True deviation” could indicate a technical performance issue, whereas “one-step dilution” represents a limitation in 
reproducibility of the MIC method and not a technical performance issue (see text for further details). Sporadic cases of 
erroneous interpretation of MIC values obtained as expected are included among “one-step dil.”. 
Figure 10. Deviations (%) from expected interpretation of AST results for each antimicrobial. Escherichia coli component of the 
EURL-AR EQAS 2018. AMP, ampicillin; AZI, azithromycin; FEP, cefepime; FOT, cefotaxime; TAZ, ceftazidime; CHL, 
chloramphenicol; CIP, ciprofloxacin; COL, colistin; ETP, ertapenem; GEN, gentamicin; IMI, imipenem; MERO, meropenem; 
NAL, nalidixic acid; SMX, sulfamethoxazole; TET, tetracycline; TGC, tigecycline; TMP, trimethoprim. “True deviation” could 
indicate a technical performance issue, whereas “one-step dilution” represents a limitation in reproducibility of the MIC method 
and not a technical performance issue (see text for further details). Sporadic cases of erroneous interpretation of MIC values 
obtained as expected are included among “one-step dil.”. 
Figure 11. Deviations (%) by participating laboratory in the Escherichia coli trial, EURL-AR EQAS 2018. The dashed line 
indicates the threshold (5%) for acceptable laboratory performance. “True deviation” could indicate a technical performance 
issue, whereas “one-step dilution” represents a limitation in reproducibility of the MIC method and not a technical performance 
issue (see text for further details). Sporadic cases of erroneous interpretation of MIC values obtained as expected are included 
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Beta-lactamase-producing E. coli 
Participants were requested to detect the 
production of beta-lactamases and classify the 
beta-lactam resistance phenotype into 
Extended-Spectrum Beta-Lactamase
(ESBL)/AmpC/carbapenemase production as a 
mandatory component. 
Guidelines for interpretation of the beta-lactam 
resistance phenotype were specified in the 
protocol (Appendix 4b) and were in agreement 
with the latest recommendations by EFSA. 
In this EQAS, EC-12.1, EC-12.3 and EC-12.8 
were ESBL producers, and EC-12.5, EC-12.6 
and EC-12.7 were carbapenemase producers. 
The remaining strains (EC-12.2 and EC-12.4) 
did not produce any beta-lactamase mediating 
ESBL/AmpC/carbapenemase phenotype. 
All 32 participants uploaded results for this part 
of the E. coli trial. The vast majority of 
laboratories (≥ 87.5%) performed correct 
detection and classification of the test strains 
(Table 4). However, twelve cases of 
misclassification (Table 4) were observed in 
nine laboratories indicating some difficulties in 
classification of beta-lactam resistance 
phenotypes.  
3.3 Performance in AST of the 
quality control strains 
Antimicrobial susceptibility test results for the 
quality control strains were evaluated based on 
the CLSI quality control ranges (Appendix 5). 
3.3.1 Enterococcus faecalis ATCC 29212 
All 28 participants in the enterococci trial 
performed AST of E. faecalis ATCC 29212 by 
MIC determination reporting a total of 308 test 
results, of which 98.7% were within the 
acceptable range (Table 5). Four laboratories 
obtained tigecycline MIC one-step dilution 
above the acceptable range. 
Strain code EC-12.1 EC-12.2 EC-12.3 EC-12.4 EC-12.5 EC-12.6 EC-12.7 EC-12.8 






























Other 1/32 (3.1%) 
4/32 
(12.5%) 
Susceptible 31/32 (96.9%) 
31/32 
(96.9%) 










blaVIM-1 blaOXA-162 blaGES-5 blaCTX-M-15 
Table 4. Expected and obtained classification of beta-lactam resistance phenotype and genetic background of each Escherichia coli 
strain, EURL-AR EQAS 2018. 
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Table 5. Antimicrobial susceptibility testing of 












Ampicillin 0/28 (0%) − − 
Chloramphenicol 0/28 (0%) − − 
Ciprofloxacin 0/28 (0%) − − 
Daptomycin 0/28 (0%) − − 
Erythromycin 0/28 (0%) − − 
Gentamicin 0/28 (0%) − − 
Linezolid 0/28 (0%) − − 
Quinu/dalfopristin  - − − 
Teicoplanin 0/28 (0%) − − 
Tetracycline 0/28 (0%) − − 
Tigecycline 4/24 (16%) − 4
Vancomycin 0/28 (0%) − − 
3.3.2 Staphylococcus aureus ATCC 29213 
All 25 participants in the staphylococci trial 
performed AST of S. aureus ATCC 29213 by 
MIC determination reporting a total of 397 test 
results, of which 98.2% were within the 
acceptable range (Table 6). The deviation for 
ciprofloxacin was obtained by Lab #36 reporting 
a MIC one-fold dilution above the highest value 
of the acceptable range. The deviations for 
penicillin were obtained by Lab # 22, 30, 41 and 
42 reporting a MIC one-fold dilution below the 
lowest value of the acceptable range, and by 
Lab # 31 and 36 reporting a MIC higher than 
one-fold dilution above the highest value of the 
acceptable range. 
Table 6. Antimicrobial susceptibility testing of 












Cefoxitin 0/24 (0%) − − 
Chloramphenicol 0/25 (0%) − − 
Ciprofloxacin 1/25 (4%) − 1
Clindamycin 0/25 (0%) − − 
Erythromycin 0/25 (0%) − − 
Fusidic acid 0/20 (0%) − − 
Gentamicin 0/25 (0%) − − 
Kanamycin 0/19 (0%) − − 
Linezolid 0/25 (0%) − − 
Penicillin 6/20 (40%) 4 2
Quinu/dalfopristin  0/24 (0%) − − 
Rifampicin 0/20 (0%) − − 
Sulfamethoxazole 0/23 (0%) − − 
Sulfa/Trimethoprim 0/4 (0%) − − 
Tetracycline 0/25 (0%) − − 
Trimethoprim 0/24 (0%) − − 
Vancomycin 0/24 (0%) − − 
3.3.3 Escherichia coli ATCC 25922 
A total of 31 out of 32 participants in the E. coli 
trial tested E. coli ATCC 25922 by MIC 
determination reporting a total of 598 test 
results, of which 98.8% were within the 
acceptable range (Table 7). The deviations for 
trimethoprim were obtained by different 
laboratories (Lab # 18, 23 and 26) and the 
remaining deviations were obtained by Lab #60. 
This laboratory realised to have performed 
typing mistakes when typing data into the 
database and informed the EQAS organizer 
that obtained results were indeed in range. 
Further details on test results of quality control 
strains are reported in Appendix 6. 
Table 7. Antimicrobial susceptibility testing of 











Ampicillin 1/31 (3.2%) 1 − 
Azithromycin no range − − 
Cefotaxime 0/58 (0%) − − 
Ceftazidime 0/59 (0%) − − 
Chloramphenicol 0/31 (0%) − − 
Ciprofloxacin 0/31 (0%) − − 
Colistin 0/31 (0%) − − 
Gentamicin 0/31 (0%) − − 
Meropenem 0/59 (0%) − − 
Nalidixic acid 0/31 (0%) − − 
Sulfamethoxazole 1/31 (3.2%) 1 − 
Tetracycline 1/31 (3.2%) 1 − 
Tigecycline 1/31 (3.2%) − 1
Trimethoprim 3/31 (9.6%) 3 − 
Cefepime 0/28 (0%) − − 
Cefotaxime/clavulanic 
acid no range − − 
Cefoxitin 0/28 (0%) − − 
Ceftazidime/clavulanic 
acid no range − − 
Ertapenem 0/28 (0%) − − 
Imipenem 0/28 (0%) − − 
Temocillin no range − − 
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4. Conclusions
This report presented the result of the EURL-
AR EQAS 2018 for E. coli, enterococci and 
staphylococci. This proficiency test evaluated 
the performance in i) MIC determination and 
interpretation, ii) enterococci species 
identification and iii) detection of relevant 
phenotypes such as methicillin resistance in S. 
aureus and beta-lactam resistance mediated by 
ESBL/AmpC/carbapenemase in E. coli. 
Participants invited to this EQAS represent 
NRL-AR from each EU MS and additional 
laboratories affiliated to the EURL-AR network 
including laboratories from non-MS and 
laboratories other than NRL-AR in MS. 
Results from NRL-AR and from one laboratory 
per non-MS were analysed in this report, 
leading to a total of 28 (24 MS and 4 non-MS), 
25 (22 MS and 3 non-MS) and 32 (28 MS and 4 
non-MS) sets of results analysed for 
enterococci, staphylococci and E. coli, 
respectively. 
In the MIC determination and interpretation 
component, three, one and no laboratories 
obtained more than 5% deviations in the 
enterococci, staphylococci and E. coli trial, 
respectively. Communication between the 
EURL-AR and these underperforming 
laboratories is ongoing to assess the causes of 
the high percentages of deviations and to 
identify possible troubleshooting procedures.  
Generally, a notable proportion of deviations 
was caused by expected MIC values close to 
breakpoint for resistance. Thus, a one-fold 
dilution difference from expected value, which is 
a limitation of MIC determination method 
reproducibility, resulted in different interpretation 
and was scored as a deviation. This is not 
indicative of any performance problem. 
However, it was also possible to identify a few 
performance issues that could be addressed in 
a relatively easy way by the involved 
laboratories such as deviations due to different 
interpretation of MIC values that were obtained 
in agreement with those expected. Notable 
deviations were those obtained in tigecycline 
and sulfamethoxazole susceptibility testing in 
enterococci and S. aureus, respectively. Testing 
of these antimicrobials may be challenging due 
to lability of the compound (in case of 
tigecycline) and specific MIC reading rules that 
may be very operator-dependent (in case of 
sulfamethoxazole). Laboratories having issues 
in detecting these phenotypes are invited to 
contact the EURL-AR that will provide 
assistance for troubleshooting.  
Enterococci species identification was 
performed correctly by all laboratories indicating 
excellent performance in this EQAS 
component. 
Also detection of methicillin resistance in S. 
aureus was correctly performed by all 
laboratories even though cefoxitin MIC 
determination yielded a few deviations. This 
suggests that at least some laboratories rely on 
methods other than cefoxitin MIC testing for 
MRSA/MSSA status determination. 
Detection of ESBL/AmpC/carbapenemase 
production in E. coli was correctly performed by 
the vast majority of laboratories. Interpretation 
of the beta-lactam resistance phenotypes 
presented challenges for a few laboratories 
highlighting the need to further support the 
network in classification of the beta-lactam 
resistance phenotypes according to the EFSA 
guidelines.  
Overall, performance in this EQAS was 
consistent with that observed in EQAS 
iterations since 2014 both regarding total 
percentage of deviations and number of 
laboratories with percentage of deviations 
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above the acceptable limit. This implies that 
further efforts should be made to ensure 
excellent AST performance across all 
laboratories in the network.  
As usual, the EURL-AR welcomes suggestions 
for improvement of future EQAS trials and 
invites the network to contribute with ideas for 
newsletters and for training needs, with the 
overall goal to continuously improve the 
knowledge and skills of the laboratories 
involved in the AMR monitoring. 
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EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
 G00-06-001/23.06.2017  
EQAS 2018 FOR E. COLI, STAPHYLOCOCCI AND ENTEROCOCCI 
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight E. coli isolates, eight 
staphylococci and eight enterococci isolates. Additionally, quality control (QC) strains E. coli 
ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), and S. aureus ATCC 29213 
(CCM 4223) will be distributed to new participants.  
It is the recipients’ responsibility to comply with national legislation, rules and regulation regarding 
the correct use and handling of the provided strains and to possess the proper equipment and 
protocols to handle these strains. 
This EQAS is specifically for NRL’s on antimicrobial resistance (NRL-AR). Laboratories 
designated to be NRL-AR do not need to sign up to participate but are automatically regarded as 
participants. You may contact the EQAS-Coordinator if you wish to inform of changes in relation to 
your level of participation in compared to previous years. The EURL-AR will be able to cover the 
expenses for one parcel, only, per EU Member State. Therefore, countries with more than one 
laboratory registered on the EURL-AR contact-list will be contacted directly to confirm which 
laboratory will be included for participation free of charge.  
The invitation to participate in the proficiency test is extended to additional participants besides 
official NRLs and to participants from laboratories which are involved in the network but are not 
designated NRLs (cost for participation will be 100 euro). 
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight E. coli, eight 
staphylococci, eight enterococci and for new participants also the QC strains mentioned above. 
Please provide the EQAS coordinator with documents or other information that can simplify 
customs procedures (e.g. specific text that should be written on the proforma invoice). To avoid 
delays, we kindly ask you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped at the end of May 2018. The 
protocol for this proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
September 14th, 2018 via the password-protected website.  
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-
protected website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. To 
comply with current EU legislation (2013/652/EU), only MIC results obtained by broth 
microdilution will be evaluated in the report. In the report, laboratories will be presented coded, 
which ensures full anonymity. The EURL-AR and the EU Commission, only, will have access to 
un-coded results. The report will be publicly available. 
Next EQAS: The next EURL-AR EQAS that we will launch are isolation of ESBL-/AmpC-
producing E. coli from caeca and meat samples in September 2018 and antimicrobial susceptibility 
testing of Salmonella and Campylobacter in October 2018. 
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
Susanne Karlsmose Pedersen 
EURL-AR EQAS-Coordinator The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
Participants in the EURL‐AR EQAS on E. coli, enterococci and staphylococci 2018
Institute  Country E. coli Enterococci S. aureus
Austrian Agency for Health and Food Safety Austria x x x
Sciensano Belgium x x x
National Diagnostic and Research Veterinary Institute Bulgaria x x x
Croatian Veterinary Institute Croatia x x x
Veterinary Services Cyprus x no no
State Veterinary Institute Praha Czech Republic x x x
National Food Institute Denmark x x x
Danish Veterinary and Food Administration, DVFA Denmark x x no
Estonian Veterinary and Food Laboratory Estonia x x x
Finnish Food Safety Authority EVIRA Finland x x x
Agence nationale de sécurité sanitaire ANSES - Laboratoire de Fougères France x x no
Federal Institute for Risk Assessment Germany x x x
Veterinary Laboratory of Chalkis Greece x no no
Central Agricultural Office Veterinary Diagnostic Directorate Hungary x x no
University of Iceland Iceland x x x
Central Veterinary Research Laboratory Ireland x x x
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy x no x
Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia x x x
National Food and Veterinary Risk Assessment Institute Lithuania x x x
Laboratoire National de Santé Luxembourg x x x
Faculty of Veterinary Medicine - Skopje North Macedonia x x no
Public Health Laboratory Malta x x x
Food and Consumer Product Safety Authority (VWA) Netherlands x x x
Central Veterinary Institute of Wageningen UR Netherlands x x x
Veterinærinstituttet Norway x x x
National Veterinary Research Institute Poland x x x
Instituto Nacional de Investigação Agrária e Veterinária Portugal x no no
Institute for Hygiene and Veterinary Public Health Romania x x x
Institute for Diagnosis and Animal Health Romania x x x
State Veterinary and Food Institute  (SVFI) Slovakia x x x
National Veterinary Institute Slovenia x x x
Laboratorio Central de Sanidad, Animal de Santa Fe Spain no no x
Laboratorio Central de Sanidad, Animal de Algete Spain no x no
VISAVET Health Surveillance Center, Complutense University Spain x x x
Centro Nacional de Alimentación (AECOSAN) Spain x no no
National Veterinary Institute, SVA Sweden x x x
Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland x x x
The Veterinary Laboratory Agency United Kingdom x x x
Color code
NRLs_results evaluated in the report
non-NRL enrolled for EQAS or extra-NRL enrolled_results not evaluated in the report
NRL from non EU MS_results evaluated in the report
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Expected MIC values
Strain ID Species Antimicrobial
DAP TIG TEI AMP CHL CIP ERY GEN LZD Q‐D TET VAN
EURL ENT 12.1 Enterococcus faecium 1 0.12 64 4 <=4 0.5 2 <=8 2 4 64 >128
EURL ENT 12.2 Enterococcus faecalis 4 0.12 <=0.5 1 8 1 <=1 16 2 8 <=1 2
EURL ENT 12.3 Enterococcus faecalis 2 0.12 <=0.5 1 64 1 >128 16 8 16 128 2
EURL ENT 12.4 Enterococcus faecium 4 0.12 >64 >64 32 >16 >128 <=8 2 1 32 >128
EURL ENT 12.5 Enterococcus faecium 8 0.06 1 >64 8 >16 2 <=8 2 4 32 32
EURL ENT 12.6 Enterococcus faecium 2 0.12 <=0.5 64 16 4 >128 1024 2 8 128 2
EURL ENT 12.7 Enterococcus faecalis 1 0.12 <=0.5 2 64 >16 >128 >1024 2 8 64 <=1
EURL ENT 12.8 Enterococcus faecalis 4 0.12 <=0.5 1 128 1 >128 1024 2 16 128 2
Expected interpretation
Strain ID Species Antimicrobial
DAP TIG TEI AMP CHL CIP ERY GEN LZD Q‐D TET VAN
EURL ENT 12.1 Enterococcus faecium S S R S S S S S S S R R
EURL ENT 12.2 Enterococcus faecalis S S S S S S S S S S S
EURL ENT 12.3 Enterococcus faecalis S S S S R S R S R R S
EURL ENT 12.4 Enterococcus faecium S S R R S R R S S S R R
EURL ENT 12.5 Enterococcus faecium R S S R S R S S S S R R
EURL ENT 12.6 Enterococcus faecium S S S R S S R R S R R S
EURL ENT 12.7 Enterococcus faecalis S S S S R R R R S R S
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Expected MIC values
Strain ID Species
VAN Q‐D LZD MUP CLN CHL CIP ERY FOX GEN SMX TET TIA TMP RIF PEN KAN FUS STR
EURL ST 12.1 Staphylococcus aureus <=1 <=0.5 <=1 <=0.5 <=0.12 <=4 1 <=0.25 8 >16 512 >16 <=0.5 <=2 >0.5 >2 >64 <=0.5 >32
EURL ST 12.2 Staphylococcus aureus <=1 <=0.5 2 <=0.5 <=0.12 8 0.5 0.5 4 <=1 >512 <=0.5 1 <=2 <=0.016 <=0.12 <=4 <=0.5 8
EURL ST 12.3 Staphylococcus aureus <=1 1 2 <=0.5 >4 8 8 <=0.25 8 <=1 <=64 >16 >4 >32 <=0.016 >2 <=4 <=0.5 8
EURL ST 12.4 Staphylococcus aureus <=1 2 2 <=0.5 1 8 <=0.25 0.5 4 <=1 <=64 <=0.5 >4 <=2 <=0.016 >2 <=4 <=0.5 8
EURL ST 12.5 Staphylococcus aureus <=1 2 2 <=0.5 >4 16 0.5 >8 4 <=1 <=64 >16 4 <=2 <=0.016 <=0.12 8 <=0.5 8
EURL ST 12.6 Staphylococcus aureus <=1 >4 2 <=0.5 >4 8 <=0.25 >8 2 <=1 <=64 >16 >4 >32 <=0.016 1 <=4 <=0.5 >32
EURL ST 12.7 Staphylococcus aureus <=1 <=0.5 2 <=0.5 <=0.12 8 <=0.25 >8 4 <=1 <=64 <=0.5 1 <=2 <=0.016 <=0.12 <=4 >4 8
EURL ST 12.8 Staphylococcus aureus <=1 <=0.5 2 <=0.5 <=0.12 8 0.5 0.5 8 <=1 >512 <=0.5 <=0.5 <=2 <=0.016 >2 <=4 <=0.5 8
Expected interpretation
Strain ID Species MRSA*
VAN Q‐D LZD MUP CLN CHL CIP ERY FOX GEN SMX TET TIA TMP RIF PEN KAN FUS STR
EURL ST 12.1 Staphylococcus aureus S S S S S S S S R R R R S S R NA R S R positive
EURL ST 12.2 Staphylococcus aureus S S S S S S S S S S S S S S S NA S S S negative
EURL ST 12.3 Staphylococcus aureus S S S S R S R S R S S R R R S NA S S S positive
EURL ST 12.4 Staphylococcus aureus S R S S R S S S S S S S R S S NA S S S negative
EURL ST 12.5 Staphylococcus aureus S R S S R S S R S S S R R S S NA S S S negative
EURL ST 12.6 Staphylococcus aureus S R S S R S S R S S S R R R S NA S S R negative
EURL ST 12.7 Staphylococcus aureus S S S S S S S R S S S S S S S NA S R S negative
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Expected MIC values
Strain ID Species
AMP MER COL CHL CIP TAZ FOT GEN NAL SMX TET TMP AZI TIG
EURL EC 12.1 Escherichia coli >64 <=0.03 <=1 <=8 <=0.015 4 >4 <=0.5 <=4 16 <=2 <=0.25 16 <=0.25
EURL EC 12.2 Escherichia coli 2 <=0.03 <=1 <=8 <=0.015 <=0.5 <=0.25 <=0.5 <=4 16 <=2 <=0.25 8 <=0.25
EURL EC 12.3 Escherichia coli >64 <=0.03 4 >128 >8 >8 >4 32 >128 >1024 >64 >32 64 <=0.25
EURL EC 12.4 Escherichia coli >64 <=0.03 <=1 <=8 0.25 <=0.5 <=0.25 >32 >128 >1024 >64 >32 8 2
EURL EC 12.5 Escherichia coli >64 4 <=1 <=8 0.03 >8 >4 2 <=4 32 <=2 <=0.25 4 <=0.25
EURL EC 12.6 Escherichia coli >64 0.5 4 >128 8 <=0.5 0.5 <=0.5 >128 >1024 >64 0.5 8 0.5
EURL EC 12.7 Escherichia coli >64 0.25 <=1 <=8 <=0.015 8 2 4 <=4 >1024 >64 >32 8 <=0.25
EURL EC 12.8 Escherichia coli >64 <=0.03 <=1 128 0.5 8 >4 <=0.5 8 >1024 >64 <=0.25 16 <=0.25
Expected interpretation
Strain ID Species
AMP MER COL CHL CIP TAZ FOT GEN NAL SMX TET TMP AZI TIG
EURL EC 12.1 Escherichia coli R S S S S R R S S S S S S S
EURL EC 12.2 Escherichia coli S S S S S S S S S S S S S S
EURL EC 12.3 Escherichia coli R S R R R R R R R R R R R S
EURL EC 12.4 Escherichia coli R S S S R S S R R R R R S R
EURL EC 12.5 Escherichia coli R R S S S R R S S S S S S S
EURL EC 12.6 Escherichia coli R R R R R S R S R R R S S S
EURL EC 12.7 Escherichia coli R R S S S R R R S R R R S S
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Expected MIC values
Strain ID Species
FOX TAZ TAZ+CL FOT FOT+CL FEP MER IMI ETP TRM
EURL EC 12.1 Escherichia coli 4 4 0.25 >64 <=0.06 >32 <=0.03 <=0.12 <=0.015 <=4
EURL EC 12.2 Escherichia coli 4 <=0.25 <=0.12 <=0.25 <=0.06 <=0.06 <=0.03 <=0.12 <=0.015 <=4
EURL EC 12.3 Escherichia coli 8 16 0.25 >64 <=0.06 >32 <=0.03 <=0.12 0.03 8
EURL EC 12.4 Escherichia coli 4 <=0.25 <=0.12 <=0.25 <=0.06 0.12 <=0.03 <=0.12 <=0.015 8
EURL EC 12.5 Escherichia coli >64 >128 >128 >64 >64 >32 8 4 0.5 128
EURL EC 12.6 Escherichia coli 8 0.5 0.5 0.5 0.5 0.5 0.5 2 0.5 >128
EURL EC 12.7 Escherichia coli 64 8 0.5 2 0.12 0.5 0.25 0.5 0.25 8
EURL EC 12.8 Escherichia coli 8 8 <=0.12 >64 <=0.06 32 <=0.03 <=0.12 0.03 4
Expected interpretation
Strain ID Species
FOX TAZ TAZ+CL* FOT FOT+CL* FEP MER IMI ETP TRM** ESBL AmpC ESBL+AmpC Carbapenemase Other None
EURL EC 12.1 Escherichia coli S R SYNERGY R SYNERGY R S S S NA YES NO NO NO NO NO
EURL EC 12.2 Escherichia coli NR NR NR NR NR NR NR NR NR NR NO NO NO NO NO YES
EURL EC 12.3 Escherichia coli S R SYNERGY R SYNERGY R S S S NA YES NO NO NO NO NO
EURL EC 12.4 Escherichia coli NR NR NR NR NR NR NR NR NR NR NO NO NO NO NO YES
EURL EC 12.5 Escherichia coli R R NO SYNERGY R NO SYNERGY R R R R NA NO NO NO YES NO NO
EURL EC 12.6 Escherichia coli S S NO SYNERGY R NO SYNERGY R R R R NA NO NO NO YES NO NO
EURL EC 12.7 Escherichia coli R R SYNERGY R SYNERGY R R S R NA NO NO NO YES NO NO
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G00-06-001/23.06.2017
Welcome letter 
EURL-AR External Quality Assurance System 2018 
Escherichia coli, staphylococci and enterococci 




Please find enclosed the bacterial strains for the EURL-AR EQAS 2018: eight E. coli, eight S. 
aureus and eight Enterococcus spp. Upon arrival to your laboratory, the strains should be stored in 
a dark place at 4C for stabs, and in a dark and cool place for freeze-dried strains.  
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for this EURL-AR 
EQAS are available: 
- Protocol for antimicrobial susceptibility testing of E. coli, staphylococci and enterococci
and test forms for reporting results
- Instructions for Opening and Reviving Lyophilised Cultures
- Subculture and Maintenance of Quality Control Strains
We ask you to test these E. coli, Enterococci and S. aureus strains for antimicrobial susceptibility. 
Detailed description of the procedures to follow for antimicrobial susceptibility testing and for 
entering your results into the interactive web database can be found in the protocol. For accessing 
the database, you need this username and password. 
Your username: xxx
 Your password: xxx
Please keep this document 
  Your username and password will not appear in other documents 
Results should be submitted to the database no later than 14th September 2018. 
Please acknowledge receipt of this parcel immediately upon arrival (to vabo@food.dtu.dk).  
Do not hesitate to contact me for further information. 
Yours sincerely, 
Susanne Karlsmose Pedersen 
EURL-AR EQAS-Coordinator 
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PROTOCOL 
For antimicrobial susceptibility testing of Escherichia coli, enterococci and staphylococci 
1 INTRODUCTION .................................................................................................................. 1 
2 OBJECTIVES ........................................................................................................................ 2 
3 OUTLINE OF THE EC/ENT/STAPH EQAS 2018 ............................................................ 2 
3.1 Shipping, receipt and storage of strains .................................................................. 2 
3.2 Suggested procedure for reconstitution of the lyophilised reference strains ...... 3 
3.3 Antimicrobial susceptibility testing ......................................................................... 3 
4 REPORTING OF RESULTS AND EVALUATION .......................................................... 6 
4.1 General recommendations for data upload ............................................................ 7 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE ............................ 7 
5.1 AST of E. coli, enterococci and staphylococci ........................................................ 8 
APPENDIX ......................................................................................................................................... 9 
_______________________________________________________________________________ 
HISTORY OF CHANGES; Protocol, version 2 
In Table 3, interpretative criteria corrected. 
_______________________________________________________________________________ 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of E. coli, enterococci and staphylococci is among the 
tasks of the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The EC/Ent/Staph 
EQAS 2018 will include AST of eight Escherichia coli, eight enterococci and eight staphylococci 
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strains and AST of reference strains E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 
(CCM 4224), and S. aureus ATCC 29213 (CCM 4223).  
The reference strains are included in the parcel only for new participants of the EQAS who did not 
receive them previously. The reference strains are original CERTIFIED cultures provided free of 
charge, and should be used for future internal quality control for antimicrobial susceptibility testing 
in your laboratory. The reference strains will not be included in the years to come. Therefore, please 
take proper care of these strains. Handle and maintain them as suggested in the manual ‘Subculture 
and Maintenance of QC Strains’ available on the EURL-AR website (see www.eurl-ar.eu).  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work.  
2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained for AST of pathogens of food- and animal-origin, with special regard to E. coli, 
enterococci and staphylococci. Further objectives are to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility of E. coli, enterococci and staphylococci reported 
to EFSA by different laboratories. 
3 OUTLINE OF THE EC/ENT/STAPH EQAS 2018 
3.1 Shipping, receipt and storage of strains 
In June 2018, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight E. coli, eight enterococci and eight staphylococci strains from the 
DTU National Food Institute. This parcel will also contain reference strains, but only for 
participants who did not receive them previously. 
All strains belong to UN3373, Biological substance, category B. Extended-spectrum beta-lactamase 
(ESBL)-producing strains as well as carbapenemase-producing strains and methicillin-resistant 
Staphylococcus aureus (MRSA) will be included in the selected material.  
It is the recipients’ responsibility to comply with national legislation, rules and regulation regarding 
the correct use and handling of the provided strains and to possess the proper equipment and 
protocols to handle these strains. The reference strains are shipped lyophilised, while the test strains 
are stab cultures. On arrival, the stab cultures must be subcultured, and all cultures should be 
adequately stored until testing. A suggested procedure for reconstitution of the lyophilised reference 
strains is presented below.  
 
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
Please refer to the document ‘Instructions for opening and reviving lyophilised cultures’ reported on 
the EURL-AR-website (see www.eurl-ar.eu). 
 
3.3 Antimicrobial susceptibility testing 
Participants should perform minimum inhibitory concentration (MIC) determination using the 
methods stated in the Commission Implementing Decision 2013/652/EU (international reference 
method (ISO standard 20776-1:2006)). For staphylococci, MIC methods should be used as well, 
according to the EFSA recommendations and the antimicrobials to test are those stated under the 
EFSA technical specifications (see Table 3). For interpretation of the results, please use the cut-off 
values listed in Tables 1, 2, 3 and 4 in this document. These values (except where indicated) 
represent the current epidemiological cut-off values developed by EUCAST (www.eucast.org), and 
allow categorisation of bacterial isolates into two categories: resistant and susceptible. A 
categorisation as intermediate is not accepted.  
Participants will not be allowed to use disk diffusion as the current regulation and recommendations 
only focus on MIC determination. 
3.3.1 E. coli  
Table 1. Antimicrobials recommended for AST of Escherichia coli and interpretive criteria 
according to table 1 in Commission Implementing Decision 2013/652/EU 
 
Antimicrobials for E. coli MIC (µg/mL) R is > 
Ampicillin, AMP 8 
Azithromycin, AZI 16* 
Cefotaxime, FOT 0.25  
Ceftazidime, TAZ 0.5  
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.064  
Colistin, COL 2 
Gentamicin, GEN 2 
Meropenem, MERO 0.125 
Nalidixic acid, NAL 16 
Sulfamethoxazole, SMX 64 
Tetracycline, TET 8 
Tigecycline, TGC 0.5* 
Trimethoprim, TMP 2 
* Tentative ECOFF  
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Beta-lactam resistance 
Confirmatory tests for ESBL/AmpC/Carbapenemase production are mandatory on all strains 
resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem  (MERO) and should be 
performed by testing the second panel of antimicrobials (Table 2 in this document corresponding to 
Table 4 in Commission Implementing Decision 2013/652/EU). 
Table 2. Antimicrobials recommended for additional AST of Escherichia coli resistant to 
cefotaxime, ceftazidime and/or meropenem and interpretive criteria according to table 4 in 
Commission Implementing Decision 2013/652/EU 
Antimicrobials for E. coli MIC (µg/mL) R is > 
Cefepime, FEP 0.125 
Cefotaxime, FOT 0.25 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 0.5 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.064 
Imipenem, IMI 0.5 
Meropenem, MERO 0.125 
Temocillin, TRM >32*
*Tentative ECOFF
Confirmatory test for ESBL production requires use of both cefotaxime (FOT) and ceftazidime 
(TAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
as a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. the MIC of the agent when tested alone (MIC FOT : FOT/CL 
or TAZ : TAZ/CL ratio ≥ 8) (CLSI M100 Table 3A, Tests for ESBLs). The presence of synergy 
indicates ESBL production.  
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO). 
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase. 
The classification of the phenotypic beta-lactam resistance results should be based on the most 
recent EFSA recommendations (see the Appendix to this protocol). It is important to notice that two 
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cut-off values apply for cefotaxime and ceftazidime: the EUCAST cut-off values (ECOFFs: 
FOT>0.25 and TAZ>0.5), which are those used to define R/S, and the screening cut-off values 
(FOT>1 and TAZ>1), which are those applied to categorise bacterial phenotypes as ESBL, AmpC, 
carbapenemase, etc. based on panel 2 results (see Appendix). The screening cut-off values are 
higher than the ECOFF values to increase sensitivity and specificity.  
 
3.3.2 Enterococci  
Table 3. Antimicrobials recommended for AST of Enterococcus spp. and interpretive criteria 
according to table 3 in Commission Implementing Decision 2013/652/EU 
 
Antimicrobials for enterococci MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Daptomycin, DAP 4 4 
Erythromycin, ERY 4 4 
Gentamicin, GEN 32 32 
Linezolid, LZD 4 4 
Quinupristin-dalfopristin (Synercid), SYN 4* Intrinsically resistant 
Teicoplanin, TEI 2 2 
Tetracycline, TET 4 4 
Tigecycline, TGC 0.25** 0.25** 
Vancomycin, VAN 4 4 
*DANMAP 2009 (www.danmap.org); **Tentative ECOFF 
 
Identification of Enterococcus spp. 
Species identification of enterococci must be performed by the NRLs using in-house methods or 
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3.3.3 Staphylococci  
Table 4. Antimicrobials recommended for AST of Staphylococcus aureus and interpretive criteria 
according to EFSA technical specifications (EFSA Journal 2012;10(10):2897) 
 
Antimicrobials for S. aureus MIC (µg/mL) R is > 
Cefoxitin, FOX  4 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP  1 
Clindamycin, CLN 0.25 
Erythromycin, ERY  1 
Fusidic acid, FUS 0.5 
Gentamicin, GEN  2 
Kanamycin, KAN 8 
Linezolid, LZD 4 
Mupirocin, MUP 0.5 
Penicillin, PEN na 
Quin.-Dalf. (Synercid), SYN   1 
Rifampicin, RIF 0.032 
Streptomycin, STR 16 
Sulfamethoxazole, SMX  128 
Tetracycline, TET  1 
Tiamulin (TIA) 2 
Trimethoprim, TMP  2 
Vancomycin, VAN 2 
            na, not available 
Identification of MRSA 
Confirmation of mecA and/or mecC presence is mandatory in this EQAS and should be 
performed by the NRLs using in-house methods or adopting the protocol available on the EURL-
AR website at www.eurl-ar.eu/233-protocols.htm. Results should be uploaded as ‘positive’ or 
‘negative’.  
 
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the test forms, and enter your results into the interactive web database. 
In addition, we kindly ask you to report in the database the tested MIC range for the staphylococci 
tests (for this organism only, as it is not included in the Commission Implementing Decision 
2013/652/EU). Finally, if you did not use the cut-off values recommended in the protocol for 
interpretation of Staphylococcus AST results, please report the breakpoints used in the database. 
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4.1 General recommendations for data upload 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database. Results must be submitted no later than September 14th, 2018. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
Results will be summarised in a report which will be publicly available. Only MIC-results obtained 
by broth microdilution will be included in the report. All data will be presented with laboratory 
codes. A laboratory code is known to the individual laboratory, whereas the complete list of 
laboratories and their codes is confidential and known only to the EURL-AR and the EU 
Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
Susanne Karlsmose Pedersen 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
E-mail: suska@food.dtu.dk 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms and the breakpoint values you used.  
Enter the EURL-AR EQAS 2018 start web page (http://eurl-ar.food.dtu.dk/01), write your 
username and password in lower-cases and press enter. Your username and password are indicated 
in the letter accompanying your strains. Do not hesitate to contact us if you experience problems 
with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
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5.1 AST of E. coli, enterococci and staphylococci 
Click on either “E. coli”, “enterococci” or “staphylococci” for input of test results based on the 
results you are going to upload.  
Click on "Start of Data Entry - Methods and Breakpoints”. 
In the next page, you can navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing and the brand 
of MIC trays, etc.  
Click on “save” and then go back using the tab “home” and enter another test page to upload 
results.  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli, Enterococcus and Staphylococcus strain. 
For E. coli strains, remember to report also the results for the ESBL/AmpC/Carbapenemase 
detection tests. 
For S. aureus strains, remember to report also the results for presence/absence of methicillin 
resistance. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on “save“ and then go back using the tab “home” and enter another test page to upload 
results.  
When uploading data on the reference strains, please enter MIC values in µg/ml. Remember to use 
the operator keys to show symbols like “equal to”, etc. 
Click on “save“. 
Review the input pages by browsing through the pages and make corrections if necessary. 
Remember to save a page if you make corrections. If you press home to leave a page without saving 
changes, you will see an error screen. In this case, click on “save“ to save your results, browse back 
to the page and then continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields because 
YOU CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive 
database.  
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APPENDIX 
 
Criteria for interpretation of Escherichia coli, panel 2 results 
 
 
Please refer to: EFSA (European Food Safety Authority) and ECDC (European Centre for Disease 
Prevention and Control),  2018. The European Union summary report on antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food in 2016. EFSA Journal 
2018;16(2):5182, 270 pp. doi:10.2903/j.efsa.2018.5182 (page 46). 
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EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
Page 1 of 28 
G00-06-001/28.06.2016 
Antimicrobial susceptibility testing of Escherichia coli, enterococci 
and staphylococci 
TEST FORMS 
Name:       
Name of laboratory: 
Name of institute:       
City:       
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TEST FORMS METHODS - Enterococci 
Which method did you use for antimicrobial susceptibility testing of enterococci in this EQAS: 
  MIC – Broth microdilution  
  MIC – Agar dilution (note: not evaluated in the final report) 
 Brand:                            
 
How many Enterococcus spp. isolates does your laboratory annually isolate:       
 
How many Enterococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility by a MIC method:       
 
Which method was followed for the preparation of the inoculum? Please describe: 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORMS METHODS - Staphylococci 
Which method did you use for antimicrobial susceptibility testing of staphylococci in this EQAS: 
  MIC – Broth microdilution  
  MIC – Agar dilution (note: not evaluated in the final report) 
 Brand:                            
How many Staphylococcus spp. isolates does your laboratory annually isolate:       
How many Staphylococcus spp. isolates does your laboratory annually test for antimicrobial 
susceptibility by a MIC method:       
Which method was followed for the preparation of the inoculum? Please describe: 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
Comments or additional information:       
Antimicrobial  General information 










Cefoxitin, FOX        ≤             ≥       
Chloramphenicol, CHL       ≤             ≥       
Ciprofloxacin, CIP        ≤             ≥       
Clindamycin, CLN       ≤             ≥       
Erythromycin, ERY        ≤             ≥       
Fusidic acid, FUS       ≤             ≥       
Gentamicin, GEN        ≤             ≥       
Kanamycin, KAN       ≤             ≥       
Linezolid, LZD       ≤             ≥       
Mupirocin, MUP       ≤             ≥       
Penicillin, PEN       ≤             ≥       
Quin.-Dalf. (Synercid), SYN         ≤             ≥       
Rifampicin, RIF       ≤             ≥       
Streptomycin, STR       ≤             ≥       
Sulfamethoxazole, SMX        ≤             ≥       
Tetracycline, TET        ≤             ≥       
Tiamulin (TIA)       ≤             ≥       
Trimethoprim, TMP        ≤             ≥       
Vancomycin, VAN       ≤             ≥       
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TEST FORMS METHODS – Escherichia coli       
 
Which method did you use for antimicrobial susceptibility testing of E. coli in this EQAS: 
  MIC – Broth microdilution  
  MIC – Agar dilution (note: not evaluated in the final report) 
 
 Brand:                            
 
 Incubation conditions:      °C/     h 
 
How many E. coli isolates does your laboratory annually isolate:       
 
How many E. coli isolates does your laboratory annually test for antimicrobial susceptibility by a 
MIC method:       
 
Which method was followed for the preparation of the inoculum? Please describe: 
 Which standard was followed (TREK, CLSI…)       
 Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)       
 Please describe in detail how you prepared the dilution of the inoculum (including the volume in 
final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 
McFarland solution in 10ml MH broth, for an expected inoculum of 1*105 CFU/ml)       
 
Comments or additional information:       
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TEST FORM - Enterococci       
Strain Antimicrobial  Results and interpretation 
 
> 


















Strain Antimicrobial  Results and interpretation 
 
> 
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TEST FORM - Enterococci                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
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TEST FORM - Enterococci                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
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TEST FORM - Enterococci                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
 
Strain Antimicrobial  Results and interpretation 
 
> 







 E. faecium 
 
 E. faecalis 
Ampicillin AMP                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Daptomycin, DAP                    
Erythromycin, ERY                    
Gentamicin, GEN                    
Linezolid, LZD                    
Quin.-Dalf. (Synercid), SYN                     
Teicoplanin, TEI                   
Tetracycline, TET                    
Tigecycline, TGC                   
Vancomycin, VAN                    
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TEST FORM - Enterococci            
Antimicrobial susceptibility testing of reference strain Enterococcus faecalis ATCC 29212  
Antimicrobial  MIC-value (μg/ml) 
Ampicillin, AMP 











The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
Page 10 of 28 
G00-06-001/28.06.2016 
TEST FORMS - Staphylococci 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus




















 Methicillin resistance (MRSA)  Positive    Negative 
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 12.2 
Cefoxitin, FOX                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Fusidic acid, FUS                   
Gentamicin, GEN                    
Kanamycin, KAN                   
Linezolid, LZD                   
Mupirocin, MUP                   
Penicillin, PEN                   
Quin.-Dalf. (Synercid), SYN                     
Rifampicin, RIF                   
Streptomycin, STR                   
 Sulfamethoxazole, SMX                    
 Tetracycline, TET                    
 Tiamulin (TIA)                   
 Trimethoprim, TMP                    
 Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 12.3 
Cefoxitin, FOX                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Fusidic acid, FUS                   
Gentamicin, GEN                    
Kanamycin, KAN                   
Linezolid, LZD                   
Mupirocin, MUP                   
Penicillin, PEN                   
Quin.-Dalf. (Synercid), SYN                     
Rifampicin, RIF                   
Streptomycin, STR                   
 Sulfamethoxazole, SMX                    
 Tetracycline, TET                    
 Tiamulin (TIA)                   
 Trimethoprim, TMP                    
 Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 12.4 
Cefoxitin, FOX                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Fusidic acid, FUS                   
Gentamicin, GEN                    
Kanamycin, KAN                   
Linezolid, LZD                   
Mupirocin, MUP                   
Penicillin, PEN                   
Quin.-Dalf. (Synercid), SYN                     
Rifampicin, RIF                   
Streptomycin, STR                   
 Sulfamethoxazole, SMX                    
 Tetracycline, TET                    
 Tiamulin (TIA)                   
 Trimethoprim, TMP                    
 Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
 
  
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
 
 





TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 12.5 
Cefoxitin, FOX                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Fusidic acid, FUS                   
Gentamicin, GEN                    
Kanamycin, KAN                   
Linezolid, LZD                   
Mupirocin, MUP                   
Penicillin, PEN                   
Quin.-Dalf. (Synercid), SYN                     
Rifampicin, RIF                   
Streptomycin, STR                   
 Sulfamethoxazole, SMX                    
 Tetracycline, TET                    
 Tiamulin (TIA)                   
 Trimethoprim, TMP                    
 Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
 
  
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
 
 





TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 12.6 
Cefoxitin, FOX                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Fusidic acid, FUS                   
Gentamicin, GEN                    
Kanamycin, KAN                   
Linezolid, LZD                   
Mupirocin, MUP                   
Penicillin, PEN                   
Quin.-Dalf. (Synercid), SYN                     
Rifampicin, RIF                   
Streptomycin, STR                   
 Sulfamethoxazole, SMX                    
 Tetracycline, TET                    
 Tiamulin (TIA)                   
 Trimethoprim, TMP                    
 Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 12.7 
Cefoxitin, FOX                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Fusidic acid, FUS                   
Gentamicin, GEN                    
Kanamycin, KAN                   
Linezolid, LZD                   
Mupirocin, MUP                   
Penicillin, PEN                   
Quin.-Dalf. (Synercid), SYN                     
Rifampicin, RIF                   
Streptomycin, STR                   
 Sulfamethoxazole, SMX                    
 Tetracycline, TET                    
 Tiamulin (TIA)                   
 Trimethoprim, TMP                    
 Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
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TEST FORMS - Staphylococci  
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
S. aureus 
 
EURL ST 12.8 
Cefoxitin, FOX                    
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                    
Clindamycin, CLN                   
Erythromycin, ERY                    
Fusidic acid, FUS                   
Gentamicin, GEN                    
Kanamycin, KAN                   
Linezolid, LZD                   
Mupirocin, MUP                   
Penicillin, PEN                   
Quin.-Dalf. (Synercid), SYN                     
Rifampicin, RIF                   
Streptomycin, STR                   
 Sulfamethoxazole, SMX                    
 Tetracycline, TET                    
 Tiamulin (TIA)                   
 Trimethoprim, TMP                    
 Vancomycin, VAN                   
 
 Methicillin resistance (MRSA)  Positive             Negative 
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TEST FORM - Staphylococci                                                         
 






Cefoxitin, FOX        
Chloramphenicol, CHL       
Ciprofloxacin, CIP        
Clindamycin, CLN       
Erythromycin, ERY        
Fusidic acid, FUS       
Gentamicin, GEN        
Kanamycin, KAN       
Linezolid, LZD       
Mupirocin, MUP       
Penicillin, PEN       
Quin.-Dalf. (Synercid), SYN         
Rifampicin, RIF       
Streptomycin, STR       
Sulfamethoxazole, SMX        
Tetracycline, TET        
Tiamulin (TIA)       
Trimethoprim, TMP        
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TEST FORM – E. coli 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.1 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) should be 
tested in the second panel for confirmatory tests for ESBL/AmpC/carbapenemase production. See 
further description of confirmatory tests in the protocol section ‘3.3.1 E. coli’. 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.1 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM – E. coli                                                            
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.2 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) should be 
tested in the second panel for confirmatory tests for ESBL/AmpC/carbapenemase production. See 
further description of confirmatory tests in the protocol section ‘3.3.1 E. coli’.                                 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.2 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):        
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TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.3 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) should be 
tested in the second panel for confirmatory tests for ESBL/AmpC/carbapenemase production. See 
further description of confirmatory tests in the protocol section ‘3.3.1 E. coli’.                                 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.3 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
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TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.4 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) should be 
tested in the second panel for confirmatory tests for ESBL/AmpC/carbapenemase production. See 
further description of confirmatory tests in the protocol section ‘3.3.1 E. coli’.                                 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.4 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):        
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TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.5 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) should be 
tested in the second panel for confirmatory tests for ESBL/AmpC/carbapenemase production. See 
further description of confirmatory tests in the protocol section ‘3.3.1 E. coli’.                                 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.5 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):        
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TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.6 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) should be 
tested in the second panel for confirmatory tests for ESBL/AmpC/carbapenemase production. See 
further description of confirmatory tests in the protocol section ‘3.3.1 E. coli’.                                 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.6 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible  
Comments (include optional genotype or other results):       
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
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TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli
EURL EC 12.7














All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) should be 
tested in the second panel for confirmatory tests for ESBL/AmpC/carbapenemase production. See 
further description of confirmatory tests in the protocol section ‘3.3.1 E. coli’.
Strain Antimicrobial  Results and interpretation 
 
> 





Cefotaxime + clavulanic acid (F/C) 
Cefoxitin, FOX 
Ceftazidime, TAZ 





Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 Other phenotype 
 Susceptible 
Comments (include optional genotype or other results): 
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
 
 




TEST FORM – E. coli 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.8 
Ampicillin, AMP                         
Azithromycin, AZT                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) and/or meropenem (MERO) should be 
tested in the second panel for confirmatory tests for ESBL/AmpC/carbapenemase production. See 
further description of confirmatory tests in the protocol section ‘3.3.1 E. coli’.                                 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL EC 12.8 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
Comments (include optional genotype or other results):       
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2018 
 
 




TEST FORM – E. coli                                                           
 










Ampicillin, AMP        
Azithromycin, AZT       
Cefotaxime, FOT       
Ceftazidime, TAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Gentamicin, GEN       
Meropenem, MERO       
Nalidixic acid, NAL       
Sulfamethoxazole, SMX       
Tetracycline, TET       
Tigecycline, TGC       
Trimethoprim, TMP       
2nd panel Cefepime, FEP       
Cefotaxime, FOT       
Cefotaxime + clavulanic acid (F/C)       
Cefoxitin, FOX       
Ceftazidime, TAZ       
Ceftazidime+ clavulanic acid (T/C)       
Ertapenem, ETP       
Imipenem, IMI       
Meropenem, MERO       
Temocillin, TRM       
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Instructions for Opening and Reviving Lyophilised Cultures       G00-06-001/01.12.2014 
Page 1 of 1 
INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
Instructions adjusted from Czech Collection of Microorganisms (CCM) document ’Instructions for 
Opening and Reviving of Freeze-Dried Bacteria and Fungi’ available on http://www.sci.muni.cz.  
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule
b. Make a file cut on the ampoule near the middle of the plug (see Figure 1)
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from
just below the plug to the pointed end
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into
the ampoule
e. Remove the pointed end of the ampoule into disinfectant
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable
solid and /or liquid media
g. Incubate the inoculated medium at appropriate conditions for several days
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of
the original ampoule before discarding
Notes:  
 Cultures should be grown on media and under conditions as recommended in the CCM
catalogue (see http://www.sci.muni.cz)
 Cultures may need at least one subculturing before they can be optimally used in experiments
 Unopened ampoules should be kept in a dark and cool place!
Figure 1: from CCM document ’Instructions for Opening 
and Reviving of Freeze-Dried Bacteria and Fungi’ available 
on http://www.sci.muni.cz 
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Page 1 of 4 
SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S24, January 2014 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A9, January 2012 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination.
 Obtain QC strains from a reliable source such as ATCC
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC
validation)
 Any changes in materials or procedure must be validated with QC before implemented
 For example: Agar and broth methods may give different QC ranges for drugs such as
glycopeptides, aminoglycosides and macrolides
 Periodically perform colony counts to check the inoculum preparation procedure
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 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing.  
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DAILY MIC QC CHART 
 
  Reference: CLSI M7-A9, page 46 
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Reference: CLSI M7-A7, page 40 Reference: CLSI M7-A9, page 47 







Ampicillin AMP 2 8
Azithromycin AZI NA NA
Cefotaxime FOT 0.03 0.12
Ceftazidime TAZ 0.06 0.5
Chloramphenicol CHL 2 8
Ciprofloxacin CIP 0.004 0.015
Colistin COL 0.25 2
Gentamicin GEN 0.25 1
Meropenem MER 0.008 0.06
Nalidixic acid NAL 1 4
Sulfamethoxazole SMX 8 32
Tetracycline TET 0.5 2
Tigecycline TGC 0.03 0.25







Cefepime FEP 0.015 0.12
Cefotaxime/clavulanic acid F/C NA na
Cefotaxime FOT 0.03 0.12
Cefoxitin FOX 2 8
Ceftazidime TAZ 0.06 0.5
Ceftazidime/clavulanic acid T/C NA NA
Ertapenem ETP 0.004 0.015
Imipenem IMI 0.06 0.25
Meropenem MER 0.008 0.06
Temocillin TRM NA NA
Legend
NA, not available







Ampicillin AMP 0.5 2
Chloramphenicol CHL 4 16
Ciprofloxacin CIP 0.25 2
Daptomycin DAP 1* 4*
Erythromycin ERY 1 4
Gentamicin GEN 4 16
Linezolid LZD 1 4
Quinupristin‐dalfopristin SYN 2 8
Teicoplanin TEI 0.25 1
Tetracycline TET 8 32
Tigecycline TGC 0.03 0.12











Cefoxitin FOX 1 4
Chloramphenicol CHL 2 16
Ciprofloxacin CIP 0.12 0.5
Clindamycin CLN 0.06 0.25
Erythromycin ERY 0.25 1
Fusidic acid FUS 0.06 0.25
Gentamicin GEN 0.12 1
Kanamycin KAN 1 4
Linezolid LZD 1 4
Mupirocin MUP NA NA
Penicillin PEN 0.25 2
Quinupristin‐dalfopristin SYN 0.25 1
Rifampicin RIF 0.004 0.016
Streptomycin STR NA NA
Sulfamethoxazole SMX 32 128
Sulfamethoxazole‐trimethoprim SXT 0 0.5
Tetracycline TET 0.12 1
Tiamulin TIA NA NA
Trimethoprim TMP 1 4
Vancomycin VAN 0.5 2
Legend
NA, not available
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Enterococcus faecalis  ATCC 29212
Lab. code Antimicrobial Operator Read_values Min. value Max. value Score
2 Ampicillin = 1 0,5 2 1
2 Chloramphenicol = 8 4 16 1
2 Ciprofloxacin = 1 0,25 2 1
2 Daptomycin = 2 1 4 1
2 Erythromycin = 4 1 4 1
2 Gentamicin <= 8 4 16 1
2 Linezolid = 2 1 4 1
2 Teicoplanin <= 0,5 0,25 1 1
2 Tetracycline = 32 8 32 1
2 Tigecycline = 0,12 0,03 0,12 1
2 Vancomycin = 2 1 4 1
4 Ampicillin 1 0,5 2 1
4 Chloramphenicol 8 4 16 1
4 Ciprofloxacin 1 0,25 2 1
4 Daptomycin 4 1 4 1
4 Erythromycin <= 1 1 4 1
4 Gentamicin 16 4 16 1
4 Linezolid 2 1 4 1
4 Teicoplanin <= 0,5 0,25 1 1
4 Tetracycline 16 8 32 1
4 Tigecycline 0,06 0,03 0,12 1
4 Vancomycin <= 1 1 4 1
9 Ampicillin = 1 0,5 2 1
9 Chloramphenicol = 8 4 16 1
9 Ciprofloxacin = 1 0,25 2 1
9 Daptomycin = 2 1 4 1
9 Erythromycin = 2 1 4 1
9 Gentamicin <= 8 4 16 1
9 Linezolid = 2 1 4 1
9 Teicoplanin <= 0,5 0,25 1 1
9 Tetracycline = 16 8 32 1
9 Tigecycline = 0,06 0,03 0,12 1
9 Vancomycin = 4 1 4 1
11 Ampicillin <= 0,5 0,5 2 1
11 Chloramphenicol <= 4 4 16 1
11 Ciprofloxacin = 0,5 0,25 2 1
11 Daptomycin = 2 1 4 1
11 Erythromycin = 4 1 4 1
11 Gentamicin = 16 4 16 1
11 Linezolid = 1 1 4 1
11 Teicoplanin <= 0,5 0,25 1 1
11 Tetracycline = 32 8 32 1
11 Tigecycline = 0,06 0,03 0,12 1
11 Vancomycin = 2 1 4 1
12 Ampicillin = 1 0,5 2 1
12 Chloramphenicol = 8 4 16 1
12 Ciprofloxacin = 1 0,25 2 1
12 Daptomycin = 2 1 4 1
12 Erythromycin = 2 1 4 1
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12 Gentamicin <= 8 4 16 1
12 Linezolid = 2 1 4 1
12 Teicoplanin <= 0,5 0,25 1 1
12 Tetracycline = 32 8 32 1
12 Tigecycline = 0,12 0,03 0,12 1
12 Vancomycin = 2 1 4 1
16 Ampicillin = 1 0,5 2 1
16 Chloramphenicol = 8 4 16 1
16 Ciprofloxacin = 1 0,25 2 1
16 Daptomycin = 2 1 4 1
16 Erythromycin = 2 1 4 1
16 Gentamicin <= 8 4 16 1
16 Linezolid = 2 1 4 1
16 Teicoplanin <= 0,5 0,25 1 1
16 Tetracycline = 32 8 32 1
16 Tigecycline = 0,25 0,03 0,12 0
16 Vancomycin = 2 1 4 1
17 Ampicillin = 1 0,5 2 1
17 Chloramphenicol = 8 4 16 1
17 Ciprofloxacin = 1 0,25 2 1
17 Daptomycin = 2 1 4 1
17 Erythromycin = 2 1 4 1
17 Gentamicin <= 8 4 16 1
17 Linezolid = 2 1 4 1
17 Teicoplanin <= 0,5 0,25 1 1
17 Tetracycline = 32 8 32 1
17 Tigecycline = 0,12 0,03 0,12 1
17 Vancomycin = 2 1 4 1
19 Ampicillin = 2 0,5 2 1
19 Chloramphenicol = 8 4 16 1
19 Ciprofloxacin = 1 0,25 2 1
19 Daptomycin = 4 1 4 1
19 Erythromycin = 2 1 4 1
19 Gentamicin = 16 4 16 1
19 Linezolid = 2 1 4 1
19 Teicoplanin <= 0,5 0,25 1 1
19 Tetracycline = 32 8 32 1
19 Tigecycline = 0,12 0,03 0,12 1
19 Vancomycin = 2 1 4 1
20 Ampicillin = 1 0,5 2 1
20 Chloramphenicol = 8 4 16 1
20 Ciprofloxacin = 1 0,25 2 1
20 Daptomycin = 4 1 4 1
20 Erythromycin = 2 1 4 1
20 Gentamicin <= 8 4 16 1
20 Linezolid = 2 1 4 1
20 Teicoplanin <= 0,5 0,25 1 1
20 Tetracycline = 32 8 32 1
20 Tigecycline = 0,25 0,03 0,12 0
20 Vancomycin <= 1 1 4 1
22 Ampicillin = 2 0,5 2 1
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22 Chloramphenicol = 8 4 16 1
22 Ciprofloxacin = 0,5 0,25 2 1
22 Daptomycin = 2 1 4 1
22 Erythromycin = 2 1 4 1
22 Gentamicin <= 8 4 16 1
22 Linezolid = 2 1 4 1
22 Teicoplanin <= 0,5 0,25 1 1
22 Tetracycline = 16 8 32 1
22 Tigecycline = 0,12 0,03 0,12 1
22 Vancomycin = 2 1 4 1
23 Ampicillin <= 0,5 0,5 2 1
23 Chloramphenicol <= 4 4 16 1
23 Ciprofloxacin 0,5 0,25 2 1
23 Daptomycin 1 1 4 1
23 Erythromycin 2 1 4 1
23 Gentamicin <= 8 4 16 1
23 Linezolid 1 1 4 1
23 Teicoplanin <= 0,5 0,25 1 1
23 Tetracycline 16 8 32 1
23 Tigecycline <= 0,03 0,03 0,12 1
23 Vancomycin <= 1 1 4 1
25 Ampicillin = 1 0,5 2 1
25 Chloramphenicol = 8 4 16 1
25 Ciprofloxacin = 1 0,25 2 1
25 Daptomycin = 2 1 4 1
25 Erythromycin = 2 1 4 1
25 Gentamicin <= 8 4 16 1
25 Linezolid = 2 1 4 1
25 Teicoplanin <= 0,5 0,25 1 1
25 Tetracycline = 32 8 32 1
25 Tigecycline = 0,25 0,03 0,12 0
25 Vancomycin = 4 1 4 1
26 Ampicillin = 1 0,5 2 1
26 Chloramphenicol = 8 4 16 1
26 Ciprofloxacin = 1 0,25 2 1
26 Daptomycin = 2 1 4 1
26 Erythromycin = 2 1 4 1
26 Gentamicin <= 8 4 16 1
26 Linezolid = 2 1 4 1
26 Teicoplanin <= 0,5 0,25 1 1
26 Tetracycline = 16 8 32 1
26 Tigecycline = 0,12 0,03 0,12 1
26 Vancomycin <= 1 1 4 1
29 Ampicillin = 1 0,5 2 1
29 Chloramphenicol = 8 4 16 1
29 Ciprofloxacin = 1 0,25 2 1
29 Daptomycin = 2 1 4 1
29 Erythromycin = 2 1 4 1
29 Gentamicin <= 8 4 16 1
29 Linezolid = 2 1 4 1
29 Teicoplanin <= 0,5 0,25 1 1
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29 Tetracycline = 16 8 32 1
29 Tigecycline = 0,06 0,03 0,12 1
29 Vancomycin = 2 1 4 1
30 Ampicillin = 1 0,5 2 1
30 Chloramphenicol = 8 4 16 1
30 Ciprofloxacin = 0,5 0,25 2 1
30 Daptomycin = 2 1 4 1
30 Erythromycin = 4 1 4 1
30 Gentamicin <= 8 4 16 1
30 Linezolid = 2 1 4 1
30 Teicoplanin <= 0,5 0,25 1 1
30 Tetracycline = 32 8 32 1
30 Tigecycline = 0,12 0,03 0,12 1
30 Vancomycin = 2 1 4 1
32 Ampicillin = 1 0,5 2 1
32 Chloramphenicol = 8 4 16 1
32 Ciprofloxacin = 0,5 0,25 2 1
32 Daptomycin = 1 1 4 1
32 Erythromycin = 2 1 4 1
32 Gentamicin <= 8 4 16 1
32 Linezolid = 2 1 4 1
32 Teicoplanin <= 0,5 0,25 1 1
32 Tetracycline = 16 8 32 1
32 Tigecycline = 0,12 0,03 0,12 1
32 Vancomycin <= 1 1 4 1
33 Ampicillin = 1 0,5 2 1
33 Chloramphenicol <= 4 4 16 1
33 Ciprofloxacin = 0,5 0,25 2 1
33 Daptomycin = 2 1 4 1
33 Erythromycin = 4 1 4 1
33 Gentamicin <= 8 4 16 1
33 Linezolid = 2 1 4 1
33 Teicoplanin <= 0,5 0,25 1 1
33 Tetracycline = 16 8 32 1
33 Tigecycline <= 0,03 0,03 0,12 1
33 Vancomycin = 2 1 4 1
34 Ampicillin <= 0,5 0,5 2 1
34 Chloramphenicol <= 4 4 16 1
34 Ciprofloxacin = 1 0,25 2 1
34 Daptomycin = 1 1 4 1
34 Erythromycin <= 1 1 4 1
34 Gentamicin <= 8 4 16 1
34 Linezolid = 1 1 4 1
34 Teicoplanin <= 0,5 0,25 1 1
34 Tetracycline = 16 8 32 1
34 Tigecycline = 0,12 0,03 0,12 1
34 Vancomycin <= 1 1 4 1
36 Ampicillin = 2 0,5 2 1
36 Chloramphenicol = 8 4 16 1
36 Ciprofloxacin = 1 0,25 2 1
36 Daptomycin = 2 1 4 1
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36 Erythromycin = 2 1 4 1
36 Gentamicin = 16 4 16 1
36 Linezolid = 2 1 4 1
36 Teicoplanin <= 0,5 0,25 1 1
36 Tetracycline = 32 8 32 1
36 Tigecycline = 0,25 0,03 0,12 0
36 Vancomycin = 4 1 4 1
39 Ampicillin = 1 0,5 2 1
39 Chloramphenicol <= 4 4 16 1
39 Ciprofloxacin = 1 0,25 2 1
39 Daptomycin = 2 1 4 1
39 Erythromycin = 2 1 4 1
39 Gentamicin <= 8 4 16 1
39 Linezolid = 2 1 4 1
39 Teicoplanin <= 0,5 0,25 1 1
39 Tetracycline = 32 8 32 1
39 Tigecycline = 0,06 0,03 0,12 1
39 Vancomycin = 2 1 4 1
40 Ampicillin = 1 0,5 2 1
40 Chloramphenicol = 4 4 16 1
40 Ciprofloxacin = 0,5 0,25 2 1
40 Daptomycin = 1 1 4 1
40 Erythromycin = 1 1 4 1
40 Gentamicin = 16 4 16 1
40 Linezolid = 1 1 4 1
40 Teicoplanin = 0,5 0,25 1 1
40 Tetracycline = 8 8 32 1
40 Tigecycline = 0,06 0,03 0,12 1
40 Vancomycin = 1 1 4 1
41 Ampicillin = 1 0,5 2 1
41 Chloramphenicol = 8 4 16 1
41 Ciprofloxacin = 0,25 0,25 2 1
41 Daptomycin = 1 1 4 1
41 Erythromycin <= 1 1 4 1
41 Gentamicin <= 8 4 16 1
41 Linezolid = 1 1 4 1
41 Teicoplanin <= 0,5 0,25 1 1
41 Tetracycline = 8 8 32 1
41 Tigecycline = 0,06 0,03 0,12 1
41 Vancomycin = 2 1 4 1
42 Ampicillin = 1 0,5 2 1
42 Chloramphenicol = 8 4 16 1
42 Ciprofloxacin = 1 0,25 2 1
42 Daptomycin = 4 1 4 1
42 Erythromycin = 2 1 4 1
42 Gentamicin <= 8 4 16 1
42 Linezolid = 2 1 4 1
42 Teicoplanin <= 0,5 0,25 1 1
42 Tetracycline = 32 8 32 1
42 Tigecycline = 0,12 0,03 0,12 1
42 Vancomycin = 2 1 4 1
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45 Ampicillin <= 0,5 0,5 2 1
45 Chloramphenicol <= 4 4 16 1
45 Ciprofloxacin = 0,5 0,25 2 1
45 Daptomycin = 2 1 4 1
45 Erythromycin = 2 1 4 1
45 Gentamicin <= 8 4 16 1
45 Linezolid = 1 1 4 1
45 Teicoplanin <= 0,5 0,25 1 1
45 Tetracycline = 16 8 32 1
45 Tigecycline = 0,06 0,03 0,12 1
45 Vancomycin = 2 1 4 1
56 Ampicillin = 2 0,5 2 1
56 Chloramphenicol = 8 4 16 1
56 Ciprofloxacin = 1 0,25 2 1
56 Daptomycin = 2 1 4 1
56 Erythromycin = 4 1 4 1
56 Gentamicin <= 8 4 16 1
56 Linezolid = 2 1 4 1
56 Teicoplanin <= 0,5 0,25 1 1
56 Tetracycline = 8 8 32 1
56 Tigecycline = 0,12 0,03 0,12 1
56 Vancomycin = 2 1 4 1
59 Ampicillin <= 0,5 0,5 2 1
59 Chloramphenicol = 8 4 16 1
59 Ciprofloxacin = 1 0,25 2 1
59 Daptomycin = 2 1 4 1
59 Erythromycin = 2 1 4 1
59 Gentamicin = 16 4 16 1
59 Linezolid = 2 1 4 1
59 Teicoplanin <= 0,5 0,25 1 1
59 Tetracycline = 32 8 32 1
59 Tigecycline = 0,12 0,03 0,12 1
59 Vancomycin = 2 1 4 1
60 Ampicillin = 1 0,5 2 1
60 Chloramphenicol = 8 4 16 1
60 Ciprofloxacin = 1 0,25 2 1
60 Daptomycin = 4 1 4 1
60 Erythromycin = 2 1 4 1
60 Gentamicin <= 8 4 16 1
60 Linezolid = 2 1 4 1
60 Teicoplanin <= 0,5 0,25 1 1
60 Tetracycline = 32 8 32 1
60 Tigecycline = 0,12 0,03 0,12 1
60 Vancomycin = 4 1 4 1
64 Ampicillin 1 0,5 2 1
64 Chloramphenicol <= 4 4 16 1
64 Ciprofloxacin 1 0,25 2 1
64 Daptomycin 2 1 4 1
64 Erythromycin <= 1 1 4 1
64 Gentamicin <= 8 4 16 1
64 Linezolid 2 1 4 1
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64 Teicoplanin <= 0,5 0,25 1 1
64 Tetracycline 32 8 32 1
64 Tigecycline 0,06 0,03 0,12 1
64 Vancomycin 4 1 4 1
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Staphylococcus aureus  ATCC 29213
Lab. code Antimicrobial Operator Read_values Min. value Max. value Score
2 Cefoxitin = 4 1 4 1
2 Chloramphenicol = 8 2 16 1
2 Ciprofloxacin <= 0.25 0.12 0.5 1
2 Clindamycin <= 0.12 0.06 0.25 1
2 Erythromycin = 0.5 0.25 1 1
2 Fusidic acid <= 0.5 0.06 0.25 1
2 Gentamicin <= 1 0.12 1 1
2 Kanamycin <= 4 1 4 1
2 Linezolid = 2 1 4 1
2 Penicillin = 0.5 0.25 2 1
2 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
2 Rifampicin <= 0.016 0.004 0.016 1
2 Sulfamethoxazole <= 64 32 128 1
2 Tetracycline <= 0.5 0.12 1 1
2 Trimethoprim <= 2 1 4 1
2 Vancomycin <= 1 0.5 2 1
4 Cefoxitin 4 1 4 1
4 Chloramphenicol 16 2 16 1
4 Ciprofloxacin <= 0.25 0.12 0.5 1
4 Clindamycin <= 0.12 0.06 0.25 1
4 Erythromycin 1 0.25 1 1
4 Fusidic acid <= 0.5 0.06 0.25 1
4 Gentamicin <= 1 0.12 1 1
4 Kanamycin <= 4 1 4 1
4 Linezolid 4 1 4 1
4 Penicillin 0.5 0.25 2 1
4 Quinupristin/dalfopristin (Synercid) 0.5 0.25 1 1
4 Rifampicin <= 0.016 0.004 0.016 1
4 Sulfamethoxazole <= 64 32 128 1
4 Tetracycline 1 0.12 1 1
4 Trimethoprim <= 2 1 4 1
4 Vancomycin <= 1 0.5 2 1
9 Cefoxitin = 2 1 4 1
9 Chloramphenicol <= 4 2 16 1
9 Ciprofloxacin <= 0.25 0.12 0.5 1
9 Clindamycin <= 0.12 0.06 0.25 1
9 Erythromycin = 0.5 0.25 1 1
9 Gentamicin <= 1 0.12 1 1
9 Linezolid = 2 1 4 1
9 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
9 Sulfamethoxazole <= 64 32 128 1
9 Tetracycline <= 0.5 0.12 1 1
9 Trimethoprim <= 2 1 4 1
9 Vancomycin <= 1 0.5 2 1
11 Cefoxitin = 4 1 4 1
11 Chloramphenicol <= 4 2 16 1
11 Ciprofloxacin = 0.5 0.12 0.5 1
11 Clindamycin <= 0.12 0.06 0.25 1
11 Erythromycin = 0.5 0.25 1 1
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11 Fusidic acid <= 0.5 0.06 0.25 1
11 Gentamicin <= 1 0.12 1 1
11 Kanamycin <= 4 1 4 1
11 Linezolid = 2 1 4 1
11 Penicillin = 0.25 0.25 2 1
11 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
11 Rifampicin <= 0.016 0.004 0.016 1
11 Sulfamethoxazole <= 64 32 128 1
11 Tetracycline <= 0.5 0.12 1 1
11 Trimethoprim = 4 1 4 1
11 Vancomycin <= 1 0.5 2 1
12 Cefoxitin = 4 1 4 1
12 Chloramphenicol = 8 2 16 1
12 Ciprofloxacin <= 0.25 0.12 0.5 1
12 Clindamycin <= 0.12 0.06 0.25 1
12 Erythromycin = 0.5 0.25 1 1
12 Fusidic acid <= 0.5 0.06 0.25 1
12 Gentamicin <= 1 0.12 1 1
12 Kanamycin <= 4 1 4 1
12 Linezolid = 2 1 4 1
12 Penicillin = 1 0.25 2 1
12 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
12 Rifampicin <= 0.016 0.004 0.016 1
12 Sulfamethoxazole <= 64 32 128 1
12 Tetracycline = 1 0.12 1 1
12 Trimethoprim <= 2 1 4 1
12 Vancomycin <= 1 0.5 2 1
17 Cefoxitin = 4 1 4 1
17 Chloramphenicol <= 4 2 16 1
17 Ciprofloxacin = 0.5 0.12 0.5 1
17 Clindamycin <= 0.12 0.06 0.25 1
17 Erythromycin = 0.5 0.25 1 1
17 Fusidic acid <= 0.5 0.06 0.25 1
17 Gentamicin <= 1 0.12 1 1
17 Kanamycin <= 4 1 4 1
17 Linezolid <= 1 1 4 1
17 Penicillin = 1 0.25 2 1
17 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
17 Rifampicin <= 0.016 0.004 0.016 1
17 Sulfamethoxazole <= 64 32 128 1
17 Tetracycline <= 0.5 0.12 1 1
17 Trimethoprim <= 2 1 4 1
17 Vancomycin <= 1 0.5 2 1
20 Cefoxitin = 4 1 4 1
20 Chloramphenicol = 16 2 16 1
20 Ciprofloxacin = 0.5 0.12 0.5 1
20 Clindamycin <= 0.12 0.06 0.25 1
20 Erythromycin = 0.5 0.25 1 1
20 Fusidic acid <= 0.5 0.06 0.25 1
20 Gentamicin <= 1 0.12 1 1
20 Kanamycin <= 4 1 4 1
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20 Linezolid = 4 1 4 1
20 Penicillin = 0.5 0.25 2 1
20 Quinupristin/dalfopristin (Synercid) = 1 0.25 1 1
20 Rifampicin <= 0.016 0.004 0.016 1
20 Sulfamethoxazole <= 64 32 128 1
20 Tetracycline = 1 0.12 1 1
20 Trimethoprim = 4 1 4 1
20 Vancomycin <= 1 0.5 2 1
21 Cefoxitin = 4 1 4 1
21 Chloramphenicol = 8 2 16 1
21 Ciprofloxacin = 0.5 0.12 0.5 1
21 Clindamycin <= 0.12 0.06 0.25 1
21 Erythromycin = 0.5 0.25 1 1
21 Fusidic acid <= 0.5 0.06 0.25 1
21 Gentamicin <= 1 0.12 1 1
21 Kanamycin <= 4 1 4 1
21 Linezolid = 2 1 4 1
21 Penicillin = 0.5 0.25 2 1
21 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
21 Rifampicin <= 0.016 0.004 0.016 1
21 Sulfamethoxazole <= 64 32 128 1
21 Tetracycline <= 0.5 0.12 1 1
21 Trimethoprim <= 2 1 4 1
21 Vancomycin <= 1 0.5 2 1
22 Cefoxitin = 2 1 4 1
22 Chloramphenicol = 8 2 16 1
22 Ciprofloxacin = 0.5 0.12 0.5 1
22 Clindamycin <= 0.12 0.06 0.25 1
22 Erythromycin = 0.5 0.25 1 1
22 Fusidic acid <= 0.5 0.06 0.25 1
22 Gentamicin <= 1 0.12 1 1
22 Kanamycin <= 4 1 4 1
22 Linezolid = 2 1 4 1
22 Penicillin <= 0.12 0.25 2 0
22 Quinupristin/dalfopristin (Synercid) = 1 0.25 1 1
22 Rifampicin <= 0.016 0.004 0.016 1
22 Sulfamethoxazole <= 64 32 128 1
22 Tetracycline <= 0.5 0.12 1 1
22 Trimethoprim <= 2 1 4 1
22 Vancomycin <= 1 0.5 2 1
23 Cefoxitin 4 1 4 1
23 Chloramphenicol 8 2 16 1
23 Ciprofloxacin <= 0.25 0.12 0.5 1
23 Clindamycin <= 0.12 0.06 0.25 1
23 Erythromycin 0.5 0.25 1 1
23 Gentamicin <= 1 0.12 1 1
23 Linezolid 2 1 4 1
23 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
23 Sulfamethoxazole <= 64 32 128 1
23 Tetracycline <= 0.5 0.12 1 1
23 Trimethoprim <= 2 1 4 1
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23 Vancomycin <= 1 0.5 2 1
25 Chloramphenicol = 16 2 16 1
25 Ciprofloxacin = 0.25 0.12 0.5 1
25 Clindamycin <= 0.25 0.06 0.25 1
25 Erythromycin = 0.5 0.25 1 1
25 Fusidic acid <= 0.25 0.06 0.25 1
25 Gentamicin <= 0.5 0.12 1 1
25 Linezolid = 4 1 4 1
25 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
25 Rifampicin <= 0.25 0.004 0.016 1
25 Tetracycline = 1 0.12 1 1
25 Vancomycin <= 1 0.5 2 1
26 Cefoxitin = 4 1 4 1
26 Chloramphenicol = 8 2 16 1
26 Ciprofloxacin <= 0.25 0.12 0.5 1
26 Clindamycin <= 0.12 0.06 0.25 1
26 Erythromycin = 0.5 0.25 1 1
26 Fusidic acid <= 0.5 0.06 0.25 1
26 Gentamicin <= 1 0.12 1 1
26 Kanamycin <= 4 1 4 1
26 Linezolid = 2 1 4 1
26 Penicillin = 0.5 0.25 2 1
26 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
26 Rifampicin <= 0.016 0.004 0.016 1
26 Sulfamethoxazole <= 64 32 128 1
26 Tetracycline <= 0.5 0.12 1 1
26 Trimethoprim <= 2 1 4 1
26 Vancomycin <= 1 0.5 2 1
29 Cefoxitin = 4 1 4 1
29 Chloramphenicol <= 4 2 16 1
29 Ciprofloxacin <= 0.25 0.12 0.5 1
29 Clindamycin <= 0.12 0.06 0.25 1
29 Erythromycin = 0.5 0.25 1 1
29 Gentamicin <= 1 0.12 1 1
29 Linezolid <= 1 1 4 1
29 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
29 Sulfamethoxazole <= 64 32 128 1
29 Tetracycline <= 0.5 0.12 1 1
29 Trimethoprim <= 2 1 4 1
29 Vancomycin <= 1 0.5 2 1
30 Cefoxitin = 4 1 4 1
30 Chloramphenicol <= 4 2 16 1
30 Ciprofloxacin <= 0.25 0.12 0.5 1
30 Clindamycin <= 0.12 0.06 0.25 1
30 Erythromycin = 0.5 0.25 1 1
30 Fusidic acid <= 0.5 0.06 0.25 1
30 Gentamicin <= 1 0.12 1 1
30 Kanamycin <= 4 1 4 1
30 Linezolid = 2 1 4 1
30 Penicillin <= 0.12 0.25 2 0
30 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
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30 Rifampicin <= 0.016 0.004 0.016 1
30 Sulfamethoxazole <= 64 32 128 1
30 Tetracycline <= 0.5 0.12 1 1
30 Trimethoprim <= 2 1 4 1
30 Vancomycin <= 1 0.5 2 1
31 Cefoxitin <= 4 1 4 1
31 Chloramphenicol <= 16 2 16 1
31 Ciprofloxacin = 0.25 0.12 0.5 1
31 Clindamycin <= 0.25 0.06 0.25 1
31 Erythromycin <= 0.5 0.25 1 1
31 Fusidic acid <= 0.5 0.06 0.25 1
31 Gentamicin <= 2 0.12 1 1
31 Kanamycin <= 8 1 4 1
31 Linezolid <= 1 1 4 1
31 Penicillin = 8 0.25 2 0
31 Quinupristin/dalfopristin (Synercid) <= 1 0.25 1 1
31 Rifampicin <= 0.032 0.004 0.016 1
31 Sulfamethoxazole <= 128 32 128 1
31 Tetracycline <= 1 0.12 1 1
31 Trimethoprim <= 2 1 4 1
31 Vancomycin <= 2 0.5 2 1
33 Cefoxitin = 4 1 4 1
33 Chloramphenicol = 8 2 16 1
33 Ciprofloxacin = 0.25 0.12 0.5 1
33 Clindamycin <= 0.25 0.06 0.25 1
33 Erythromycin = 0.5 0.25 1 1
33 Fusidic acid <= 0.25 0.06 0.25 1
33 Gentamicin = 0.5 0.12 1 1
33 Linezolid = 2 1 4 1
33 Penicillin = 0.5 0.25 2 1
33 Tetracycline <= 0.5 0.12 1 1
33 Trimethoprim = 1 1 4 1
34 Cefoxitin = 2 1 4 1
34 Chloramphenicol = 8 2 16 1
34 Ciprofloxacin <= 0.25 0.12 0.5 1
34 Clindamycin <= 0.12 0.06 0.25 1
34 Erythromycin = 0.5 0.25 1 1
34 Fusidic acid <= 0.5 0.06 0.25 1
34 Gentamicin <= 1 0.12 1 1
34 Kanamycin <= 4 1 4 1
34 Linezolid = 2 1 4 1
34 Penicillin = 0.25 0.25 2 1
34 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
34 Rifampicin <= 0.016 0.004 0.016 1
34 Sulfamethoxazole <= 64 32 128 1
34 Tetracycline <= 0.5 0.12 1 1
34 Trimethoprim <= 2 1 4 1
34 Vancomycin <= 1 0.5 2 1
36 Cefoxitin = 4 1 4 1
36 Chloramphenicol = 8 2 16 1
36 Ciprofloxacin = 1 0.12 0.5 0
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36 Clindamycin = 0.25 0.06 0.25 1
36 Erythromycin = 0.5 0.25 1 1
36 Fusidic acid <= 0.5 0.06 0.25 1
36 Gentamicin <= 1 0.12 1 1
36 Kanamycin <= 4 1 4 1
36 Linezolid = 4 1 4 1
36 Penicillin = 32 0.25 2 0
36 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
36 Rifampicin <= 0.016 0.004 0.016 1
36 Sulfamethoxazole <= 64 32 128 1
36 Tetracycline = 1 0.12 1 1
36 Trimethoprim <= 2 1 4 1
36 Vancomycin <= 1 0.5 2 1
39 Cefoxitin = 2 1 4 1
39 Chloramphenicol = 8 2 16 1
39 Ciprofloxacin <= 0.25 0.12 0.5 1
39 Clindamycin <= 0.12 0.06 0.25 1
39 Erythromycin = 0.5 0.25 1 1
39 Gentamicin <= 1 0.12 1 1
39 Linezolid = 2 1 4 1
39 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
39 Sulfamethoxazole <= 64 32 128 1
39 Tetracycline <= 0.5 0.12 1 1
39 Trimethoprim <= 2 1 4 1
39 Vancomycin <= 1 0.5 2 1
40 Cefoxitin = 2 1 4 1
40 Chloramphenicol = 8 2 16 1
40 Ciprofloxacin = 0.25 0.12 0.5 1
40 Clindamycin = 0.12 0.06 0.25 1
40 Erythromycin = 0.5 0.25 1 1
40 Fusidic acid = 0.25 0.06 0.25 1
40 Gentamicin = 1 0.12 1 1
40 Kanamycin = 4 1 4 1
40 Linezolid = 2 1 4 1
40 Penicillin = 0.5 0.25 2 1
40 Quinupristin/dalfopristin (Synercid) = 1 0.25 1 1
40 Rifampicin = 0.016 0.004 0.016 1
40 Sulfamethoxazole = 128 32 128 1
40 Tetracycline = 0.5 0.12 1 1
40 Trimethoprim = 2 1 4 1
40 Vancomycin = 1 0.5 2 1
41 Cefoxitin = 1 1 4 1
41 Chloramphenicol = 8 2 16 1
41 Ciprofloxacin <= 0.25 0.12 0.5 1
41 Clindamycin = 0.25 0.06 0.25 1
41 Erythromycin = 0.5 0.25 1 1
41 Gentamicin <= 1 0.12 1 1
41 Kanamycin <= 4 1 4 1
41 Linezolid = 2 1 4 1
41 Penicillin <= 0.12 0.25 2 0
41 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
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41 Rifampicin <= 0.016 0.004 0.016 1
41 Sulfamethoxazole <= 64 32 128 1
41 Tetracycline <= 0.5 0.12 1 1
41 Trimethoprim <= 2 1 4 1
41 Vancomycin <= 1 0.5 2 1
42 Cefoxitin = 4 1 4 1
42 Chloramphenicol = 8 2 16 1
42 Ciprofloxacin <= 0.25 0.12 0.5 1
42 Clindamycin <= 0.12 0.06 0.25 1
42 Erythromycin = 0.5 0.25 1 1
42 Fusidic acid <= 0.5 0.06 0.25 1
42 Gentamicin <= 1 0.12 1 1
42 Kanamycin <= 4 1 4 1
42 Linezolid = 2 1 4 1
42 Penicillin <= 0.12 0.25 2 0
42 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
42 Rifampicin <= 0.016 0.004 0.016 1
42 Sulfamethoxazole <= 64 32 128 1
42 Tetracycline <= 0.5 0.12 1 1
42 Trimethoprim <= 2 1 4 1
42 Vancomycin <= 1 0.5 2 1
45 Cefoxitin = 4 1 4 1
45 Chloramphenicol = 8 2 16 1
45 Ciprofloxacin = 0.5 0.12 0.5 1
45 Clindamycin <= 0.12 0.06 0.25 1
45 Erythromycin = 0.5 0.25 1 1
45 Fusidic acid <= 0.5 0.06 0.25 1
45 Gentamicin <= 1 0.12 1 1
45 Kanamycin <= 4 1 4 1
45 Linezolid = 2 1 4 1
45 Penicillin = 0.25 0.25 2 1
45 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
45 Rifampicin <= 0.016 0.004 0.016 1
45 Sulfamethoxazole = 128 32 128 1
45 Tetracycline <= 0.5 0.12 1 1
45 Trimethoprim <= 2 1 4 1
45 Vancomycin <= 1 0.5 2 1
56 Cefoxitin = 2 1 4 1
56 Chloramphenicol = 8 2 16 1
56 Ciprofloxacin <= 0.25 0.12 0.5 1
56 Clindamycin <= 0.12 0.06 0.25 1
56 Erythromycin = 0.5 0.25 1 1
56 Fusidic acid <= 0.5 0.06 0.25 1
56 Gentamicin <= 1 0.12 1 1
56 Kanamycin <= 4 1 4 1
56 Linezolid = 2 1 4 1
56 Penicillin = 0.25 0.25 2 1
56 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
56 Rifampicin <= 0.016 0.004 0.016 1
56 Sulfamethoxazole <= 64 32 128 1
56 Tetracycline <= 0.5 0.12 1 1
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56 Trimethoprim <= 2 1 4 1
56 Vancomycin <= 1 0.5 2 1
59 Cefoxitin = 4 1 4 1
59 Chloramphenicol = 8 2 16 1
59 Ciprofloxacin <= 0.25 0.12 0.5 1
59 Clindamycin <= 0.12 0.06 0.25 1
59 Erythromycin = 0.5 0.25 1 1
59 Fusidic acid <= 0.5 0.06 0.25 1
59 Gentamicin <= 1 0.12 1 1
59 Kanamycin <= 4 1 4 1
59 Linezolid = 2 1 4 1
59 Penicillin = 0.5 0.25 2 1
59 Quinupristin/dalfopristin (Synercid) <= 0.5 0.25 1 1
59 Rifampicin <= 0.016 0.004 0.016 1
59 Sulfamethoxazole <= 64 32 128 1
59 Tetracycline <= 0.5 0.12 1 1
59 Trimethoprim <= 2 1 4 1
59 Vancomycin <= 1 0.5 2 1
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Escherichia coli  ATCC 25922
Lab. code Antimicrobial Operator Read_values Min. value Max. value Score
2 Ampicillin = 8 2.0 8.0 1
2 Cefepime <= 0.06 0.016 0.12 1
2 Cefotaxime <= 0.25 0.03 0.12 1
2 Cefotaxime <= 0.25 0.03 0.12 1
2 Cefoxitin = 4 2.0 8.0 1
2 Ceftazidime <= 0.5 0.06 0.5 1
2 Ceftazidime = 0.25 0.06 0.5 1
2 Chloramphenicol <= 8 2.0 8.0 1
2 Ciprofloxacin <= 0.015 0.004 0.016 1
2 Colistin <= 1 0.25 2.0 1
2 Ertapenem <= 0.015 0.004 0.016 1
2 Gentamicin <= 0.5 0.25 1.0 1
2 Imipenem <= 0.12 0.06 0.25 1
2 Meropenem <= 0.03 0.008 0.06 1
2 Meropenem <= 0.03 0.008 0.06 1
2 Nalidixic acid <= 4 1.0 4.0 1
2 Sulfamethoxazole = 32 8.0 32.0 1
2 Tetracycline <= 2 0.5 2.0 1
2 Tigecycline <= 0.25 0.03 0.25 1
2 Trimethoprim = 0.5 0.5 2.0 1
4 Ampicillin 8 2.0 8.0 1
4 Cefepime <= 0.06 0.016 0.12 1
4 Cefotaxime <= 0.25 0.03 0.12 1
4 Cefotaxime <= 0.25 0.03 0.12 1
4 Cefoxitin 4 2.0 8.0 1
4 Ceftazidime <= 0.5 0.06 0.5 1
4 Ceftazidime <= 0.25 0.06 0.5 1
4 Chloramphenicol <= 8 2.0 8.0 1
4 Ciprofloxacin <= 0.015 0.004 0.016 1
4 Colistin <= 1 0.25 2.0 1
4 Ertapenem <= 0.015 0.004 0.016 1
4 Gentamicin <= 0.5 0.25 1.0 1
4 Imipenem 0.25 0.06 0.25 1
4 Meropenem <= 0.03 0.008 0.06 1
4 Meropenem <= 0.03 0.008 0.06 1
4 Nalidixic acid <= 4 1.0 4.0 1
4 Sulfamethoxazole 32 8.0 32.0 1
4 Tetracycline <= 2 0.5 2.0 1
4 Tigecycline <= 0.25 0.03 0.25 1
4 Trimethoprim 1 0.5 2.0 1
6 Ampicillin = 8 2.0 8.0 1
6 Cefepime <= 0.06 0.016 0.12 1
6 Cefotaxime <= 0.25 0.03 0.12 1
6 Cefotaxime <= 0.25 0.03 0.12 1
6 Cefoxitin = 8 2.0 8.0 1
6 Ceftazidime <= 0.5 0.06 0.5 1
6 Ceftazidime <= 0.25 0.06 0.5 1
6 Chloramphenicol <= 8 2.0 8.0 1
6 Ciprofloxacin <= 0.015 0.004 0.016 1
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6 Colistin <= 1 0.25 2.0 1
6 Ertapenem <= 0.015 0.004 0.016 1
6 Gentamicin = 1 0.25 1.0 1
6 Imipenem <= 0.12 0.06 0.25 1
6 Meropenem <= 0.03 0.008 0.06 1
6 Meropenem <= 0.03 0.008 0.06 1
6 Nalidixic acid <= 4 1.0 4.0 1
6 Sulfamethoxazole = 32 8.0 32.0 1
6 Tetracycline <= 2 0.5 2.0 1
6 Tigecycline <= 0.25 0.03 0.25 1
6 Trimethoprim = 1 0.5 2.0 1
9 Ampicillin = 4 2.0 8.0 1
9 Cefepime = 0.06 0.016 0.12 1
9 Cefotaxime <= 0.25 0.03 0.12 1
9 Cefoxitin = 4 2.0 8.0 1
9 Ceftazidime <= 0.5 0.06 0.5 1
9 Ceftazidime <= 0.25 0.06 0.5 1
9 Chloramphenicol <= 8 2.0 8.0 1
9 Ciprofloxacin <= 0.015 0.004 0.016 1
9 Colistin <= 1 0.25 2.0 1
9 Ertapenem <= 0.015 0.004 0.016 1
9 Gentamicin <= 0.5 0.25 1.0 1
9 Imipenem <= 0.12 0.06 0.25 1
9 Meropenem <= 0.03 0.008 0.06 1
9 Meropenem <= 0.03 0.008 0.06 1
9 Nalidixic acid <= 4 1.0 4.0 1
9 Sulfamethoxazole = 16 8.0 32.0 1
9 Tetracycline <= 2 0.5 2.0 1
9 Tigecycline <= 0.25 0.03 0.25 1
9 Trimethoprim = 1 0.5 2.0 1
11 Ampicillin = 4 2.0 8.0 1
11 Cefepime <= 0.06 0.016 0.12 1
11 Cefotaxime <= 0.25 0.03 0.12 1
11 Cefotaxime <= 0.25 0.03 0.12 1
11 Cefoxitin = 4 2.0 8.0 1
11 Ceftazidime <= 0.5 0.06 0.5 1
11 Ceftazidime <= 0.25 0.06 0.5 1
11 Chloramphenicol <= 8 2.0 8.0 1
11 Ciprofloxacin <= 0.015 0.004 0.016 1
11 Colistin <= 1 0.25 2.0 1
11 Ertapenem <= 0.015 0.004 0.016 1
11 Gentamicin <= 0.5 0.25 1.0 1
11 Imipenem <= 0.12 0.06 0.25 1
11 Meropenem <= 0.03 0.008 0.06 1
11 Meropenem <= 0.03 0.008 0.06 1
11 Nalidixic acid <= 4 1.0 4.0 1
11 Sulfamethoxazole = 16 8.0 32.0 1
11 Tetracycline <= 2 0.5 2.0 1
11 Tigecycline <= 0.25 0.03 0.25 1
11 Trimethoprim = 0.5 0.5 2.0 1
12 Ampicillin = 2 2.0 8.0 1
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12 Cefepime <= 0.06 0.016 0.12 1
12 Cefotaxime <= 0.25 0.03 0.12 1
12 Cefotaxime <= 0.25 0.03 0.12 1
12 Cefoxitin = 2 2.0 8.0 1
12 Ceftazidime <= 0.5 0.06 0.5 1
12 Ceftazidime <= 0.25 0.06 0.5 1
12 Chloramphenicol <= 8 2.0 8.0 1
12 Ciprofloxacin <= 0.015 0.004 0.016 1
12 Colistin <= 1 0.25 2.0 1
12 Ertapenem <= 0.015 0.004 0.016 1
12 Gentamicin <= 0.5 0.25 1.0 1
12 Imipenem = 0.25 0.06 0.25 1
12 Meropenem <= 0.03 0.008 0.06 1
12 Meropenem <= 0.03 0.008 0.06 1
12 Nalidixic acid <= 4 1.0 4.0 1
12 Sulfamethoxazole = 16 8.0 32.0 1
12 Tetracycline <= 2 0.5 2.0 1
12 Tigecycline <= 0.25 0.03 0.25 1
12 Trimethoprim = 0.5 0.5 2.0 1
16 Ampicillin = 4 2.0 8.0 1
16 Cefepime <= 0.06 0.016 0.12 1
16 Cefotaxime <= 0.25 0.03 0.12 1
16 Cefotaxime <= 0.25 0.03 0.12 1
16 Cefoxitin = 4 2.0 8.0 1
16 Ceftazidime <= 0.5 0.06 0.5 1
16 Ceftazidime <= 0.25 0.06 0.5 1
16 Chloramphenicol <= 8 2.0 8.0 1
16 Ciprofloxacin <= 0.015 0.004 0.016 1
16 Colistin <= 1 0.25 2.0 1
16 Ertapenem <= 0.015 0.004 0.016 1
16 Gentamicin <= 0.5 0.25 1.0 1
16 Imipenem <= 0.12 0.06 0.25 1
16 Meropenem <= 0.03 0.008 0.06 1
16 Meropenem <= 0.03 0.008 0.06 1
16 Nalidixic acid <= 4 1.0 4.0 1
16 Sulfamethoxazole = 16 8.0 32.0 1
16 Tetracycline <= 2 0.5 2.0 1
16 Tigecycline <= 0.25 0.03 0.25 1
16 Trimethoprim = 0.5 0.5 2.0 1
17 Ampicillin = 8 2.0 8.0 1
17 Cefepime <= 0.06 0.016 0.12 1
17 Cefotaxime <= 0.25 0.03 0.12 1
17 Cefotaxime <= 0.25 0.03 0.12 1
17 Cefoxitin = 4 2.0 8.0 1
17 Ceftazidime <= 0.5 0.06 0.5 1
17 Ceftazidime <= 0.25 0.06 0.5 1
17 Chloramphenicol <= 8 2.0 8.0 1
17 Ciprofloxacin <= 0.015 0.004 0.016 1
17 Colistin <= 1 0.25 2.0 1
17 Ertapenem <= 0.015 0.004 0.016 1
17 Gentamicin <= 0.5 0.25 1.0 1
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17 Imipenem <= 0.12 0.06 0.25 1
17 Meropenem <= 0.03 0.008 0.06 1
17 Meropenem <= 0.03 0.008 0.06 1
17 Nalidixic acid <= 4 1.0 4.0 1
17 Sulfamethoxazole = 16 8.0 32.0 1
17 Tetracycline <= 2 0.5 2.0 1
17 Tigecycline <= 0.25 0.03 0.25 1
17 Trimethoprim = 0.5 0.5 2.0 1
18 Ampicillin = 4 2.0 8.0 1
18 Cefepime <= 0.06 0.016 0.12 1
18 Cefotaxime <= 0.25 0.03 0.12 1
18 Cefotaxime <= 0.25 0.03 0.12 1
18 Cefoxitin = 4 2.0 8.0 1
18 Ceftazidime <= 0.5 0.06 0.5 1
18 Ceftazidime <= 0.25 0.06 0.5 1
18 Chloramphenicol <= 8 2.0 8.0 1
18 Ciprofloxacin <= 0.015 0.004 0.016 1
18 Colistin <= 1 0.25 2.0 1
18 Ertapenem <= 0.015 0.004 0.016 1
18 Gentamicin <= 0.5 0.25 1.0 1
18 Imipenem <= 0.12 0.06 0.25 1
18 Meropenem <= 0.03 0.008 0.06 1
18 Meropenem <= 0.03 0.008 0.06 1
18 Nalidixic acid <= 4 1.0 4.0 1
18 Sulfamethoxazole = 32 8.0 32.0 1
18 Tetracycline <= 2 0.5 2.0 1
18 Tigecycline <= 0.25 0.03 0.25 1
18 Trimethoprim <= 0.25 0.5 2.0 0
19 Ampicillin = 8 2.0 8.0 1
19 Cefepime <= 0.06 0.016 0.12 1
19 Cefotaxime <= 0.25 0.03 0.12 1
19 Cefotaxime <= 0.25 0.03 0.12 1
19 Cefoxitin = 4 2.0 8.0 1
19 Ceftazidime <= 0.5 0.06 0.5 1
19 Ceftazidime <= 0.25 0.06 0.5 1
19 Chloramphenicol <= 8 2.0 8.0 1
19 Ciprofloxacin <= 0.015 0.004 0.016 1
19 Colistin <= 1 0.25 2.0 1
19 Ertapenem <= 0.015 0.004 0.016 1
19 Gentamicin <= 0.5 0.25 1.0 1
19 Imipenem <= 0.12 0.06 0.25 1
19 Meropenem <= 0.03 0.008 0.06 1
19 Meropenem <= 0.03 0.008 0.06 1
19 Nalidixic acid <= 4 1.0 4.0 1
19 Sulfamethoxazole = 32 8.0 32.0 1
19 Tetracycline <= 2 0.5 2.0 1
19 Tigecycline <= 0.25 0.03 0.25 1
19 Trimethoprim = 0.5 0.5 2.0 1
20 Ampicillin = 4 2.0 8.0 1
20 Cefepime <= 0.06 0.016 0.12 1
20 Cefotaxime <= 0.25 0.03 0.12 1
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20 Cefotaxime <= 0.25 0.03 0.12 1
20 Cefoxitin = 4 2.0 8.0 1
20 Ceftazidime <= 0.5 0.06 0.5 1
20 Ceftazidime <= 0.25 0.06 0.5 1
20 Chloramphenicol <= 8 2.0 8.0 1
20 Ciprofloxacin <= 0.015 0.004 0.016 1
20 Colistin <= 1 0.25 2.0 1
20 Ertapenem <= 0.015 0.004 0.016 1
20 Gentamicin <= 0.5 0.25 1.0 1
20 Imipenem <= 0.12 0.06 0.25 1
20 Meropenem <= 0.03 0.008 0.06 1
20 Meropenem <= 0.03 0.008 0.06 1
20 Nalidixic acid <= 4 1.0 4.0 1
20 Sulfamethoxazole = 16 8.0 32.0 1
20 Tetracycline <= 2 0.5 2.0 1
20 Tigecycline <= 0.25 0.03 0.25 1
20 Trimethoprim = 0.5 0.5 2.0 1
21 Ampicillin = 4 2.0 8.0 1
21 Cefepime <= 0.06 0.016 0.12 1
21 Cefotaxime <= 0.25 0.03 0.12 1
21 Cefotaxime <= 0.25 0.03 0.12 1
21 Cefoxitin = 4 2.0 8.0 1
21 Ceftazidime <= 0.5 0.06 0.5 1
21 Ceftazidime <= 0.25 0.06 0.5 1
21 Chloramphenicol <= 8 2.0 8.0 1
21 Ciprofloxacin <= 0.015 0.004 0.016 1
21 Colistin <= 1 0.25 2.0 1
21 Ertapenem <= 0.015 0.004 0.016 1
21 Gentamicin <= 0.5 0.25 1.0 1
21 Imipenem <= 0.12 0.06 0.25 1
21 Meropenem <= 0.03 0.008 0.06 1
21 Meropenem <= 0.03 0.008 0.06 1
21 Nalidixic acid <= 4 1.0 4.0 1
21 Sulfamethoxazole = 32 8.0 32.0 1
21 Tetracycline <= 2 0.5 2.0 1
21 Tigecycline <= 0.25 0.03 0.25 1
21 Trimethoprim = 0.5 0.5 2.0 1
22 Ampicillin = 2 2.0 8.0 1
22 Cefepime <= 0.06 0.016 0.12 1
22 Cefotaxime <= 0.25 0.03 0.12 1
22 Cefotaxime <= 0.25 0.03 0.12 1
22 Cefoxitin = 4 2.0 8.0 1
22 Ceftazidime <= 0.5 0.06 0.5 1
22 Ceftazidime <= 0.25 0.06 0.5 1
22 Chloramphenicol <= 8 2.0 8.0 1
22 Ciprofloxacin <= 0.015 0.004 0.016 1
22 Colistin <= 1 0.25 2.0 1
22 Ertapenem <= 0.015 0.004 0.016 1
22 Gentamicin <= 0.5 0.25 1.0 1
22 Imipenem <= 0.12 0.06 0.25 1
22 Meropenem <= 0.03 0.008 0.06 1
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22 Meropenem <= 0.03 0.008 0.06 1
22 Nalidixic acid <= 4 1.0 4.0 1
22 Sulfamethoxazole = 16 8.0 32.0 1
22 Tetracycline <= 2 0.5 2.0 1
22 Tigecycline <= 0.25 0.03 0.25 1
22 Trimethoprim = 0.5 0.5 2.0 1
23 Ampicillin = 4 2.0 8.0 1
23 Cefepime <= 0.06 0.016 0.12 1
23 Cefotaxime <= 0.25 0.03 0.12 1
23 Cefotaxime <= 0.25 0.03 0.12 1
23 Cefoxitin = 2 2.0 8.0 1
23 Ceftazidime <= 0.5 0.06 0.5 1
23 Ceftazidime <= 0.25 0.06 0.5 1
23 Chloramphenicol <= 8 2.0 8.0 1
23 Ciprofloxacin <= 0.015 0.004 0.016 1
23 Colistin <= 1 0.25 2.0 1
23 Ertapenem <= 0.015 0.004 0.016 1
23 Gentamicin <= 0.5 0.25 1.0 1
23 Imipenem <= 0.12 0.06 0.25 1
23 Meropenem <= 0.03 0.008 0.06 1
23 Meropenem <= 0.03 0.008 0.06 1
23 Nalidixic acid <= 4 1.0 4.0 1
23 Sulfamethoxazole = 16 8.0 32.0 1
23 Tetracycline <= 2 0.5 2.0 1
23 Tigecycline <= 0.25 0.03 0.25 1
23 Trimethoprim <= 0.25 0.5 2.0 0
25 Ampicillin = 4 2.0 8.0 1
25 Cefepime <= 0.06 0.016 0.12 1
25 Cefotaxime <= 0.25 0.03 0.12 1
25 Cefotaxime <= 0.25 0.03 0.12 1
25 Cefoxitin = 8 2.0 8.0 1
25 Ceftazidime <= 0.5 0.06 0.5 1
25 Ceftazidime = 0.5 0.06 0.5 1
25 Chloramphenicol <= 8 2.0 8.0 1
25 Ciprofloxacin <= 0.015 0.004 0.016 1
25 Colistin <= 1 0.25 2.0 1
25 Ertapenem <= 0.015 0.004 0.016 1
25 Gentamicin = 1 0.25 1.0 1
25 Imipenem <= 0.12 0.06 0.25 1
25 Meropenem <= 0.03 0.008 0.06 1
25 Meropenem <= 0.03 0.008 0.06 1
25 Nalidixic acid <= 4 1.0 4.0 1
25 Sulfamethoxazole <= 8 8.0 32.0 1
25 Tetracycline <= 2 0.5 2.0 1
25 Tigecycline <= 0.25 0.03 0.25 1
25 Trimethoprim = 0.5 0.5 2.0 1
26 Ampicillin = 4 2.0 8.0 1
26 Cefotaxime <= 0.25 0.03 0.12 1
26 Ceftazidime <= 0.5 0.06 0.5 1
26 Chloramphenicol <= 8 2.0 8.0 1
26 Ciprofloxacin <= 0.015 0.004 0.016 1
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
26 Colistin <= 1 0.25 2.0 1
26 Gentamicin = 1 0.25 1.0 1
26 Meropenem <= 0.03 0.008 0.06 1
26 Nalidixic acid <= 4 1.0 4.0 1
26 Sulfamethoxazole = 16 8.0 32.0 1
26 Tetracycline <= 2 0.5 2.0 1
26 Tigecycline <= 0.25 0.03 0.25 1
26 Trimethoprim <= 0.25 0.5 2.0 0
29 Ampicillin = 4 2.0 8.0 1
29 Cefepime <= 0.06 0.016 0.12 1
29 Cefotaxime <= 0.25 0.03 0.12 1
29 Cefotaxime <= 0.25 0.03 0.12 1
29 Cefoxitin = 2 2.0 8.0 1
29 Ceftazidime <= 0.5 0.06 0.5 1
29 Ceftazidime = 0.5 0.06 0.5 1
29 Chloramphenicol <= 8 2.0 8.0 1
29 Ciprofloxacin <= 0.015 0.004 0.016 1
29 Colistin <= 1 0.25 2.0 1
29 Ertapenem <= 0.015 0.004 0.016 1
29 Gentamicin <= 0.5 0.25 1.0 1
29 Imipenem <= 0.12 0.06 0.25 1
29 Meropenem <= 0.03 0.008 0.06 1
29 Meropenem <= 0.03 0.008 0.06 1
29 Nalidixic acid <= 4 1.0 4.0 1
29 Sulfamethoxazole = 32 8.0 32.0 1
29 Tetracycline <= 2 0.5 2.0 1
29 Tigecycline <= 0.25 0.03 0.25 1
29 Trimethoprim = 1 0.5 2.0 1
30 Ampicillin = 8 2.0 8.0 1
30 Cefepime <= 0.06 0.016 0.12 1
30 Cefotaxime <= 0.25 0.03 0.12 1
30 Cefotaxime <= 0.25 0.03 0.12 1
30 Cefoxitin = 4 2.0 8.0 1
30 Ceftazidime <= 0.5 0.06 0.5 1
30 Ceftazidime = 0.5 0.06 0.5 1
30 Chloramphenicol <= 8 2.0 8.0 1
30 Ciprofloxacin <= 0.015 0.004 0.016 1
30 Colistin <= 1 0.25 2.0 1
30 Ertapenem <= 0.015 0.004 0.016 1
30 Gentamicin <= 0.5 0.25 1.0 1
30 Imipenem = 0.25 0.06 0.25 1
30 Meropenem <= 0.03 0.008 0.06 1
30 Meropenem <= 0.03 0.008 0.06 1
30 Nalidixic acid <= 4 1.0 4.0 1
30 Sulfamethoxazole = 16 8.0 32.0 1
30 Tetracycline <= 2 0.5 2.0 1
30 Tigecycline <= 0.25 0.03 0.25 1
30 Trimethoprim = 1 0.5 2.0 1
33 Ampicillin = 8 2.0 8.0 1
33 Cefepime <= 0.06 0.016 0.12 1
33 Cefotaxime <= 0.25 0.03 0.12 1
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
33 Cefotaxime <= 0.25 0.03 0.12 1
33 Cefoxitin = 4 2.0 8.0 1
33 Ceftazidime <= 0.5 0.06 0.5 1
33 Ceftazidime <= 0.25 0.06 0.5 1
33 Chloramphenicol <= 8 2.0 8.0 1
33 Ciprofloxacin <= 0.015 0.004 0.016 1
33 Colistin = 2 0.25 2.0 1
33 Ertapenem <= 0.015 0.004 0.016 1
33 Gentamicin <= 0.5 0.25 1.0 1
33 Imipenem <= 0.12 0.06 0.25 1
33 Meropenem <= 0.03 0.008 0.06 1
33 Meropenem <= 0.03 0.008 0.06 1
33 Nalidixic acid <= 4 1.0 4.0 1
33 Sulfamethoxazole = 32 8.0 32.0 1
33 Tetracycline <= 2 0.5 2.0 1
33 Tigecycline <= 0.25 0.03 0.25 1
33 Trimethoprim = 1 0.5 2.0 1
34 Ampicillin = 8 2.0 8.0 1
34 Cefepime <= 0.06 0.016 0.12 1
34 Cefotaxime <= 0.25 0.03 0.12 1
34 Cefotaxime <= 0.25 0.03 0.12 1
34 Cefoxitin = 4 2.0 8.0 1
34 Ceftazidime <= 0.5 0.06 0.5 1
34 Ceftazidime <= 0.25 0.06 0.5 1
34 Chloramphenicol <= 8 2.0 8.0 1
34 Ciprofloxacin <= 0.015 0.004 0.016 1
34 Colistin <= 1 0.25 2.0 1
34 Ertapenem <= 0.015 0.004 0.016 1
34 Gentamicin <= 0.5 0.25 1.0 1
34 Imipenem = 0.25 0.06 0.25 1
34 Meropenem <= 0.03 0.008 0.06 1
34 Meropenem <= 0.03 0.008 0.06 1
34 Nalidixic acid <= 4 1.0 4.0 1
34 Sulfamethoxazole = 16 8.0 32.0 1
34 Tetracycline <= 2 0.5 2.0 1
34 Tigecycline <= 0.25 0.03 0.25 1
34 Trimethoprim = 0.5 0.5 2.0 1
36 Ampicillin = 4 2.0 8.0 1
36 Cefepime <= 0.06 0.016 0.12 1
36 Cefotaxime <= 0.25 0.03 0.12 1
36 Cefotaxime <= 0.25 0.03 0.12 1
36 Cefoxitin = 4 2.0 8.0 1
36 Ceftazidime <= 0.5 0.06 0.5 1
36 Ceftazidime <= 0.25 0.06 0.5 1
36 Chloramphenicol <= 8 2.0 8.0 1
36 Ciprofloxacin <= 0.015 0.004 0.016 1
36 Colistin <= 1 0.25 2.0 1
36 Ertapenem <= 0.015 0.004 0.016 1
36 Gentamicin <= 0.5 0.25 1.0 1
36 Imipenem <= 0.12 0.06 0.25 1
36 Meropenem <= 0.03 0.008 0.06 1
The 24th EURL-AR Proficiency Test Enterococci, Staphylococci and Escherichia coli (2018), final version, 1 ed.
36 Meropenem <= 0.03 0.008 0.06 1
36 Nalidixic acid <= 4 1.0 4.0 1
36 Sulfamethoxazole = 32 8.0 32.0 1
36 Tetracycline <= 2 0.5 2.0 1
36 Tigecycline <= 0.25 0.03 0.25 1
36 Trimethoprim = 1 0.5 2.0 1
37 Ampicillin = 4 2.0 8.0 1
37 Cefotaxime <= 0.25 0.03 0.12 1
37 Ceftazidime <= 0.5 0.06 0.5 1
37 Chloramphenicol <= 8 2.0 8.0 1
37 Ciprofloxacin <= 0.015 0.004 0.016 1
37 Colistin <= 1 0.25 2.0 1
37 Gentamicin <= 0.5 0.25 1.0 1
37 Meropenem <= 0.03 0.008 0.06 1
37 Nalidixic acid <= 4 1.0 4.0 1
37 Sulfamethoxazole = 16 8.0 32.0 1
37 Tetracycline <= 2 0.5 2.0 1
37 Tigecycline <= 0.25 0.03 0.25 1
37 Trimethoprim = 0.5 0.5 2.0 1
38 Ampicillin = 4 2.0 8.0 1
38 Cefepime <= 0.06 0.016 0.12 1
38 Cefotaxime <= 0.25 0.03 0.12 1
38 Cefotaxime <= 0.25 0.03 0.12 1
38 Cefoxitin = 4 2.0 8.0 1
38 Ceftazidime <= 0.5 0.06 0.5 1
38 Ceftazidime <= 0.25 0.06 0.5 1
38 Chloramphenicol <= 8 2.0 8.0 1
38 Ciprofloxacin <= 0.015 0.004 0.016 1
38 Colistin <= 1 0.25 2.0 1
38 Ertapenem <= 0.015 0.004 0.016 1
38 Gentamicin <= 0.5 0.25 1.0 1
38 Imipenem = 0.25 0.06 0.25 1
38 Meropenem <= 0.03 0.008 0.06 1
38 Meropenem <= 0.03 0.008 0.06 1
38 Nalidixic acid <= 4 1.0 4.0 1
38 Sulfamethoxazole = 16 8.0 32.0 1
38 Tetracycline <= 2 0.5 2.0 1
38 Tigecycline <= 0.25 0.03 0.25 1
38 Trimethoprim = 0.5 0.5 2.0 1
39 Ampicillin = 4 2.0 8.0 1
39 Cefepime <= 0.06 0.016 0.12 1
39 Cefotaxime <= 0.25 0.03 0.12 1
39 Cefotaxime <= 0.25 0.03 0.12 1
39 Cefoxitin = 4 2.0 8.0 1
39 Ceftazidime <= 0.5 0.06 0.5 1
39 Ceftazidime <= 0.25 0.06 0.5 1
39 Chloramphenicol <= 8 2.0 8.0 1
39 Ciprofloxacin <= 0.015 0.004 0.016 1
39 Colistin <= 1 0.25 2.0 1
39 Ertapenem <= 0.015 0.004 0.016 1
39 Gentamicin <= 0.5 0.25 1.0 1
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39 Imipenem <= 0.12 0.06 0.25 1
39 Meropenem <= 0.03 0.008 0.06 1
39 Meropenem <= 0.03 0.008 0.06 1
39 Nalidixic acid <= 4 1.0 4.0 1
39 Sulfamethoxazole = 32 8.0 32.0 1
39 Tetracycline <= 2 0.5 2.0 1
39 Tigecycline <= 0.25 0.03 0.25 1
39 Trimethoprim <= 0.5 0.5 2.0 1
40 Ampicillin = 2 2.0 8.0 1
40 Cefepime = 0.06 0.016 0.12 1
40 Cefotaxime = 0.12 0.03 0.12 1
40 Cefotaxime = 0.12 0.03 0.12 1
40 Cefoxitin = 2 2.0 8.0 1
40 Ceftazidime = 0.5 0.06 0.5 1
40 Ceftazidime = 0.5 0.06 0.5 1
40 Chloramphenicol = 8 2.0 8.0 1
40 Ciprofloxacin = 0.015 0.004 0.016 1
40 Colistin = 1 0.25 2.0 1
40 Ertapenem = 0.015 0.004 0.016 1
40 Gentamicin = 0.5 0.25 1.0 1
40 Imipenem = 0.25 0.06 0.25 1
40 Meropenem = 0.03 0.008 0.06 1
40 Meropenem = 0.03 0.008 0.06 1
40 Nalidixic acid = 4 1.0 4.0 1
40 Sulfamethoxazole = 16 8.0 32.0 1
40 Tetracycline = 2 0.5 2.0 1
40 Tigecycline = 0.25 0.03 0.25 1
40 Trimethoprim = 0.5 0.5 2.0 1
41 Ampicillin = 2 2.0 8.0 1
41 Cefepime <= 0.06 0.016 0.12 1
41 Cefotaxime <= 0.25 0.03 0.12 1
41 Cefotaxime <= 0.25 0.03 0.12 1
41 Cefoxitin = 2 2.0 8.0 1
41 Ceftazidime <= 0.5 0.06 0.5 1
41 Ceftazidime <= 0.5 0.06 0.5 1
41 Chloramphenicol <= 8 2.0 8.0 1
41 Ciprofloxacin <= 0.015 0.004 0.016 1
41 Colistin <= 1 0.25 2.0 1
41 Ertapenem <= 0.015 0.004 0.016 1
41 Gentamicin = 1 0.25 1.0 1
41 Imipenem <= 0.12 0.06 0.25 1
41 Meropenem = 0.06 0.008 0.06 1
41 Meropenem = 0.06 0.008 0.06 1
41 Nalidixic acid <= 4 1.0 4.0 1
41 Sulfamethoxazole = 16 8.0 32.0 1
41 Tetracycline <= 2 0.5 2.0 1
41 Tigecycline <= 0.25 0.03 0.25 1
41 Trimethoprim = 0.5 0.5 2.0 1
42 Ampicillin = 8 2.0 8.0 1
42 Cefepime <= 0.06 0.016 0.12 1
42 Cefotaxime <= 0.25 0.03 0.12 1
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42 Cefotaxime <= 0.25 0.03 0.12 1
42 Cefoxitin = 2 2.0 8.0 1
42 Ceftazidime <= 0.5 0.06 0.5 1
42 Ceftazidime <= 0.25 0.06 0.5 1
42 Chloramphenicol <= 8 2.0 8.0 1
42 Ciprofloxacin <= 0.015 0.004 0.016 1
42 Colistin <= 1 0.25 2.0 1
42 Ertapenem <= 0.015 0.004 0.016 1
42 Gentamicin <= 0.5 0.25 1.0 1
42 Imipenem <= 0.12 0.06 0.25 1
42 Meropenem <= 0.03 0.008 0.06 1
42 Meropenem <= 0.03 0.008 0.06 1
42 Nalidixic acid <= 4 1.0 4.0 1
42 Sulfamethoxazole = 32 8.0 32.0 1
42 Tetracycline <= 2 0.5 2.0 1
42 Tigecycline <= 0.25 0.03 0.25 1
42 Trimethoprim = 1 0.5 2.0 1
45 Ampicillin = 4 2.0 8.0 1
45 Cefepime <= 0.06 0.016 0.12 1
45 Cefotaxime <= 0.25 0.03 0.12 1
45 Cefotaxime <= 0.25 0.03 0.12 1
45 Cefoxitin = 4 2.0 8.0 1
45 Ceftazidime <= 0.5 0.06 0.5 1
45 Ceftazidime = 0.5 0.06 0.5 1
45 Chloramphenicol <= 8 2.0 8.0 1
45 Ciprofloxacin <= 0.015 0.004 0.016 1
45 Colistin <= 1 0.25 2.0 1
45 Ertapenem <= 0.015 0.004 0.016 1
45 Gentamicin <= 0.5 0.25 1.0 1
45 Imipenem = 0.25 0.06 0.25 1
45 Meropenem <= 0.03 0.008 0.06 1
45 Meropenem <= 0.03 0.008 0.06 1
45 Nalidixic acid <= 4 1.0 4.0 1
45 Sulfamethoxazole = 32 8.0 32.0 1
45 Tetracycline <= 2 0.5 2.0 1
45 Tigecycline <= 0.25 0.03 0.25 1
45 Trimethoprim = 0.5 0.5 2.0 1
56 Ampicillin = 4 2.0 8.0 1
56 Cefepime <= 0.06 0.016 0.12 1
56 Cefotaxime <= 0.25 0.03 0.12 1
56 Cefotaxime <= 0.25 0.03 0.12 1
56 Cefoxitin = 2 2.0 8.0 1
56 Ceftazidime <= 0.5 0.06 0.5 1
56 Ceftazidime <= 0.25 0.06 0.5 1
56 Chloramphenicol <= 8 2.0 8.0 1
56 Ciprofloxacin <= 0.015 0.004 0.016 1
56 Colistin <= 1 0.25 2.0 1
56 Ertapenem <= 0.015 0.004 0.016 1
56 Gentamicin <= 0.5 0.25 1.0 1
56 Imipenem <= 0.12 0.06 0.25 1
56 Meropenem <= 0.03 0.008 0.06 1
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56 Meropenem <= 0.03 0.008 0.06 1
56 Nalidixic acid <= 4 1.0 4.0 1
56 Sulfamethoxazole = 16 8.0 32.0 1
56 Tetracycline <= 2 0.5 2.0 1
56 Tigecycline <= 0.25 0.03 0.25 1
56 Trimethoprim = 0.5 0.5 2.0 1
59 Ampicillin = 4 2.0 8.0 1
59 Cefepime <= 0.06 0.016 0.12 1
59 Cefotaxime <= 0.25 0.03 0.12 1
59 Cefotaxime <= 0.25 0.03 0.12 1
59 Cefoxitin = 4 2.0 8.0 1
59 Ceftazidime <= 0.5 0.06 0.5 1
59 Ceftazidime = 0.5 0.06 0.5 1
59 Chloramphenicol <= 8 2.0 8.0 1
59 Ciprofloxacin <= 0.015 0.004 0.016 1
59 Colistin <= 1 0.25 2.0 1
59 Ertapenem <= 0.015 0.004 0.016 1
59 Gentamicin <= 0.5 0.25 1.0 1
59 Imipenem = 0.25 0.06 0.25 1
59 Meropenem <= 0.03 0.008 0.06 1
59 Meropenem <= 0.03 0.008 0.06 1
59 Nalidixic acid <= 4 1.0 4.0 1
59 Sulfamethoxazole = 16 8.0 32.0 1
59 Tetracycline <= 2 0.5 2.0 1
59 Tigecycline <= 0.25 0.03 0.25 1
59 Trimethoprim = 0.5 0.5 2.0 1
60 Ampicillin <= 0.25 2.0 8.0 0
60 Cefotaxime <= 0.25 0.03 0.12 1
60 Ceftazidime <= 0.5 0.06 0.5 1
60 Chloramphenicol <= 8 2.0 8.0 1
60 Ciprofloxacin <= 0.015 0.004 0.016 1
60 Colistin <= 1 0.25 2.0 1
60 Gentamicin <= 0.5 0.25 1.0 1
60 Meropenem <= 0.03 0.008 0.06 1
60 Nalidixic acid <= 4 1.0 4.0 1
60 Sulfamethoxazole <= 2 8.0 32.0 0
60 Tetracycline <= 0.25 0.5 2.0 0
60 Tigecycline = 4 0.03 0.25 0
60 Trimethoprim <= 8 0.5 2.0 1
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Enterococci - summary of results
Antimicrobial
Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested Correct Tested
Ampicillin AMP 24 27 28 28 28 28 28 28 28 28 28 28 28 28 28 28
Chloramphenicol CHL 28 28 28 28 21 28 26 28 28 28 27 28 28 28 28 28
Ciprofloxacin CIP 28 28 28 28 28 28 28 28 28 28 8 28 28 28 28 28
Daptomycin DAP 28 28 28 28 28 28 27 28 4 28 27 27 28 28 26 28
Erythromycin ERY 27 28 28 28 28 28 28 28 27 28 28 28 28 28 28 28
Gentamicin GEN 28 28 28 28 28 28 28 28 28 28 28 28 28 28 28 28
Linezolid LZD 28 28 28 28 27 28 28 28 28 28 28 28 28 28 27 28
Quinupristin/dalfopristin (Synercid) SYN 26 27 na na na na 28 28 27 28 23 26 na na na na
Teicoplanin TEI 28 28 28 28 28 28 28 28 27 28 28 28 28 28 28 28
Tetracycline TET 28 28 28 28 28 28 28 28 28 28 28 28 28 28 28 28
Tigecycline TGC 25 27 24 27 25 28 25 28 26 28 25 27 25 27 22 28
Vancomycin VAN 27 28 28 28 28 28 27 28 27 28 28 28 28 28 28 28


































Ampicillin AMP 3,0 11,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Chloramphenicol CHL 0,0 0,0 0,0 0,0 7,0 25,0 2,0 7,1 0,0 0,0 1,0 3,6 0,0 0,0 0,0 0,0
Ciprofloxacin CIP 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 20,0 71,4 0,0 0,0 0,0 0,0
Daptomycin DAP 0,0 0,0 0,0 0,0 0,0 0,0 1,0 3,6 24,0 85,7 0,0 0,0 0,0 0,0 2,0 7,1
Erythromycin ERY 1,0 3,6 0,0 0,0 0,0 0,0 0,0 0,0 1,0 3,6 0,0 0,0 0,0 0,0 0,0 0,0
Gentamicin GEN 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Linezolid LZD 0,0 0,0 0,0 0,0 1,0 3,6 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 3,6
Quinupristin/dalfopristin (Synercid) SYN 1,0 3,7 na na na na 0,0 0,0 1,0 3,6 3,0 11,5 na na na na
Teicoplanin TEI 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 3,6 0,0 0,0 0,0 0,0 0,0 0,0
Tetracycline TET 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Tigecycline TGC 2,0 7,4 3,0 11,1 3,0 10,7 3,0 10,7 2,0 7,1 2,0 7,4 2,0 7,4 6,0 21,4
Vancomycin VAN 1,0 3,6 0,0 0,0 0,0 0,0 1,0 3,6 1,0 3,6 0,0 0,0 0,0 0,0 0,0 0,0
Excluded from report (≥ 25% deviations)
EURL ENT-12.7 EURL ENT-12.8
EURL ENT-12.1 EURL ENT-12.2 EURL ENT-12.3 EURL ENT-12.4 EURL ENT-12.5 EURL ENT-12.6 EURL ENT-12.7 EURL ENT-12.8
EURL ENT-12.1 EURL ENT-12.2 EURL ENT-12.3 EURL ENT-12.4 EURL ENT-12.5 EURL ENT-12.6
na, not applicable
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Staphylococcus aureus  - summary of results
ANTIMICROBIAL
Correct Total Correct Total Correct Total Correct Total Correct Total Correct Total Correct Total Correct Total
Cefoxitin FOX 24 24 24 24 23 24 24 24 23 24 23 24 24 24 22 24
Chloramphenicol CHL 25 25 25 25 25 25 25 25 25 25 24 25 25 25 25 25
Ciprofloxacin CIP 11 25 25 25 24 25 25 25 24 25 24 25 25 25 25 25
Clindamycin CLN 25 25 25 25 25 25 23 25 21 24 25 25 25 25 25 25
Erythromycin ERY 25 25 25 25 25 25 25 25 21 24 25 25 25 25 25 25
Fusidic acid FUS 24 24 23 24 24 24 24 24 24 24 24 24 24 24 23 24
Gentamicin GEN 25 25 25 25 25 25 25 25 25 25 24 25 25 25 25 25
Kanamycin KAN 22 22 22 22 22 22 22 22 20 22 22 22 22 22 22 22
Linezolid LZD 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25
Mupirocin MUP 23 23 22 23 23 23 23 23 23 23 23 23 23 23 23 23
Quinupristin/dalfopristin (Synercid) SYN 24 24 24 24 5 24 23 24 20 24 24 24 24 24 24 24
Rifampicin RIF 23 23 23 23 23 23 23 23 23 23 22 22 23 23 23 23
Streptomycin STR 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22
Sulfamethoxazole SMX 22 23 21 23 21 23 22 23 23 23 21 23 22 23 23 23
Tetracycline TET 25 25 25 25 25 25 24 25 25 25 25 25 24 25 25 25
Tiamulin TIA 23 23 23 23 23 23 23 23 22 23 23 23 23 23 23 23
Trimethoprim TMP 24 24 24 24 24 24 24 24 23 24 24 24 21 24 24 24
Vancomycin VAN 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24


































Cefoxitin FOX 0,0 0,0 0,0 0,0 1,0 4,2 0,0 0,0 1,0 4,2 1,0 4,2 0,0 0,0 2,0 8,3
Chloramphenicol CHL 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 4,0 0,0 0,0 0,0 0,0
Ciprofloxacin CIP 14,0 56,0 0,0 0,0 1,0 4,0 0,0 0,0 1,0 4,0 1,0 4,0 0,0 0,0 0,0 0,0
Clindamycin CLN 0,0 0,0 0,0 0,0 0,0 0,0 2,0 8,0 3,0 12,5 0,0 0,0 0,0 0,0 0,0 0,0
Erythromycin ERY 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 3,0 12,5 0,0 0,0 0,0 0,0 0,0 0,0
Fusidic acid FUS 0,0 0,0 1,0 4,2 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 4,2
Gentamicin GEN 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 4,0 0,0 0,0 0,0 0,0
Kanamycin KAN 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 2,0 9,1 0,0 0,0 0,0 0,0 0,0 0,0
Linezolid LZD 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Mupirocin MUP 0,0 0,0 1,0 4,3 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Quinupristin/dalfopristin (Synercid) SYN 0,0 0,0 0,0 0,0 19,0 79,2 1,0 4,2 4,0 16,7 0,0 0,0 0,0 0,0 0,0 0,0
Rifampicin RIF 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Streptomycin STR 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Sulfamethoxazole SMX 1,0 4,3 2,0 8,7 2,0 8,7 1,0 4,3 0,0 0,0 2,0 8,7 1,0 4,3 0,0 0,0
Tetracycline TET 0,0 0,0 0,0 0,0 0,0 0,0 1,0 4,0 0,0 0,0 0,0 0,0 1,0 4,0 0,0 0,0
Tiamulin TIA 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 4,3 0,0 0,0 0,0 0,0 0,0 0,0
Trimethoprim TMP 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 4,2 0,0 0,0 3,0 12,5 0,0 0,0
Vancomycin VAN 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Excluded from report ≥ 25% deviations)
EURL ST‐12.7 EURL ST‐12.8
EURL ST‐12.1 EURL ST‐12.2 EURL ST‐12.3 EURL ST‐12.4 EURL ST‐12.5 EURL ST‐12.6 EURL ST‐12.7 EURL ST‐12.8
EURL ST‐12.1 EURL ST‐12.2 EURL ST‐12.3 EURL ST‐12.4 EURL ST‐12.5 EURL ST‐12.6
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Escherichia coli  ‐ summary of results
ANTIMICROBIAL
Correct Total Correct Total Correct Total Correct Total Correct Total Correct Total Correct Total Correct Total
Ampicillin AMP 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32
Azithromycin AZI 32 32 32 32 30 32 32 32 32 32 32 32 32 32 30 32
Cefepime FEP 32 32 na na 32 32 na na 32 32 31 31 32 32 32 32
Cefotaxime FOT 64 64 31 32 64 64 31 32 64 64 63 63 64 64 64 64
Cefoxitin FOX 32 32 na na 31 32 na na 32 32 25 30 32 32 30 32
Ceftazidime TAZ 64 64 31 32 64 64 32 32 64 64 61 63 64 64 64 64
Chloramphenicol CHL 32 32 31 32 31 32 32 32 32 32 32 32 32 32 32 32
Ciprofloxacin CIP 32 32 32 32 32 32 32 32 32 32 32 32 31 32 31 32
Colistin COL 32 32 32 32 32 32 32 32 32 32 26 30 32 32 32 32
Ertapenem ETP 32 32 na na 32 32 na na 32 32 31 31 31 32 32 32
Gentamicin GEN 32 32 32 32 32 32 32 32 32 32 32 32 3 32 32 32
Imipenem IMI 32 32 na na 32 32 na na 32 32 18 29 22 31 32 32
Meropenem MERO 64 64 32 32 64 64 32 32 64 64 56 63 61 64 64 64
Nalidixic acid NAL 32 32 32 32 32 32 32 32 32 32 32 32 31 32 32 32
Sulfamethoxazole SMX 32 32 31 32 32 32 32 32 32 32 32 32 32 32 31 32
Tetracycline TET 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32
Tigecycline TGC 32 32 32 32 32 32 28 32 32 32 32 32 32 32 32 32
Trimethoprim TMP 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32


































Ampicillin AMP 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Azithromycin AZI 0,0 0,0 0,0 0,0 2,0 6,3 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 2,0 6,3
Cefepime FEP 0,0 0,0 na na 0,0 0,0 na na 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Cefotaxime FOT 0,0 0,0 1,0 3,1 0,0 0,0 1,0 3,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Cefoxitin FOX 0,0 0,0 na na 1,0 3,1 na na 0,0 0,0 5,0 16,7 0,0 0,0 2,0 6,3
Ceftazidime TAZ 0,0 0,0 1,0 3,1 0,0 0,0 0,0 0,0 0,0 0,0 2,0 3,2 0,0 0,0 0,0 0,0
Chloramphenicol CHL 0,0 0,0 1,0 3,1 1,0 3,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Ciprofloxacin CIP 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 3,1 1,0 3,1
Colistin COL 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 4,0 13,3 0,0 0,0 0,0 0,0
Ertapenem ETP 0,0 0,0 na na 0,0 0,0 na na 0,0 0,0 0,0 0,0 1,0 3,1 0,0 0,0
Gentamicin GEN 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 29,0 90,6 0,0 0,0
Imipenem IMI 0,0 0,0 na na 0,0 0,0 na na 0,0 0,0 11,0 37,9 9,0 29,0 0,0 0,0
Meropenem MERO 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 7,0 11,1 3,0 4,7 0,0 0,0
Nalidixic acid NAL 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 3,1 0,0 0,0
Sulfamethoxazole SMX 0,0 0,0 1,0 3,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 1,0 3,1
Tetracycline TET 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Tigecycline TGC 0,0 0,0 0,0 0,0 0,0 0,0 4,0 12,5 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Trimethoprim TMP 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Excluded from the report (≥ 25% deviations)
EURL EC‐12.7 EURL EC‐12.8
EURL EC‐12.1 EURL EC‐12.2 EURL EC‐12.3 EURL EC‐12.4 EURL EC‐12.5 EURL EC‐12.6 EURL EC‐12.7 EURL EC‐12.8
EURL EC‐12.1 EURL EC‐12.2 EURL EC‐12.3 EURL EC‐12.4 EURL EC‐12.5 EURL EC‐12.6
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Enterococci - deviations
Lab code Strain ID Antimicrobial Read_value Exp_value Interp. Exp_interp.
22 EURL ENT-12.1 Ampicillin AMP 8 4 R S
25 EURL ENT-12.1 Ampicillin AMP 8 4 R S
34 EURL ENT-12.1 Ampicillin AMP 4 4 R S
11 EURL ENT-12.1 Erythromycin ERY 16 2 R S
22 EURL ENT-12.1 Quinupristin/dalfopristin (Synercid) SYN 8 4 R S
34 EURL ENT-12.1 Tigecycline TGC 0,5 0,12 R S
64 EURL ENT-12.1 Tigecycline TGC 0,5 0,12 R S
64 EURL ENT-12.1 Vancomycin VAN <= 1 > 128 S R
34 EURL ENT-12.2 Tigecycline TGC 0,5 0,12 R S
41 EURL ENT-12.2 Tigecycline TGC 0,5 0,12 R S
64 EURL ENT-12.2 Tigecycline TGC 0,5 0,12 R S
11 EURL ENT-12.3 Chloramphenicol CHL 32 64 S R
12 EURL ENT-12.3 Chloramphenicol CHL 32 64 S R
17 EURL ENT-12.3 Chloramphenicol CHL 32 64 S R
22 EURL ENT-12.3 Chloramphenicol CHL 32 64 S R
30 EURL ENT-12.3 Chloramphenicol CHL 32 64 S R
33 EURL ENT-12.3 Chloramphenicol CHL 32 64 S R
40 EURL ENT-12.3 Chloramphenicol CHL 32 64 S R
17 EURL ENT-12.3 Linezolid LZD 2 8 S R
34 EURL ENT-12.3 Tigecycline TGC 0,5 0,12 R S
41 EURL ENT-12.3 Tigecycline TGC 0,5 0,12 R S
64 EURL ENT-12.3 Tigecycline TGC 0,5 0,12 R S
2 EURL ENT-12.4 Chloramphenicol CHL 32 32 R S
34 EURL ENT-12.4 Chloramphenicol CHL 16 32 R S
36 EURL ENT-12.4 Daptomycin DAP 8 4 R S
17 EURL ENT-12.4 Tigecycline TGC 0,5 0,12 R S
34 EURL ENT-12.4 Tigecycline TGC 0,5 0,12 R S
41 EURL ENT-12.4 Tigecycline TGC 0,5 0,12 R S
23 EURL ENT-12.4 Vancomycin VAN > 128 > 128 S R
2 EURL ENT-12.5 Daptomycin DAP 4 8 S R
4 EURL ENT-12.5 Daptomycin DAP 4 8 S R
11 EURL ENT-12.5 Daptomycin DAP 4 8 S R
12 EURL ENT-12.5 Daptomycin DAP 4 8 S R
16 EURL ENT-12.5 Daptomycin DAP 4 8 S R
17 EURL ENT-12.5 Daptomycin DAP 2 8 S R
22 EURL ENT-12.5 Daptomycin DAP 4 8 S R
23 EURL ENT-12.5 Daptomycin DAP 4 8 S R
25 EURL ENT-12.5 Daptomycin DAP 4 8 S R
26 EURL ENT-12.5 Daptomycin DAP 4 8 S R
30 EURL ENT-12.5 Daptomycin DAP 2 8 S R
32 EURL ENT-12.5 Daptomycin DAP 2 8 S R
33 EURL ENT-12.5 Daptomycin DAP 4 8 S R
34 EURL ENT-12.5 Daptomycin DAP 4 8 S R
36 EURL ENT-12.5 Daptomycin DAP 4 8 S R
39 EURL ENT-12.5 Daptomycin DAP 4 8 S R
40 EURL ENT-12.5 Daptomycin DAP 4 8 S R
41 EURL ENT-12.5 Daptomycin DAP 1 8 S R
42 EURL ENT-12.5 Daptomycin DAP 4 8 S R
45 EURL ENT-12.5 Daptomycin DAP 2 8 S R
56 EURL ENT-12.5 Daptomycin DAP 1 8 S R
59 EURL ENT-12.5 Daptomycin DAP 4 8 S R
60 EURL ENT-12.5 Daptomycin DAP 4 8 S R
64 EURL ENT-12.5 Daptomycin DAP 4 8 S R
11 EURL ENT-12.5 Erythromycin ERY 16 2 R S
64 EURL ENT-12.5 Quinupristin/dalfopristin (Synercid) SYN 2 4 R S
39 EURL ENT-12.5 Teicoplanin TEI 16 1 R S
34 EURL ENT-12.5 Tigecycline TGC 0,5 0,06 R S
41 EURL ENT-12.5 Tigecycline TGC 0,5 0,06 R S
41 EURL ENT-12.5 Vancomycin VAN 2 32 S R
2 EURL ENT-12.6 Chloramphenicol CHL 32 16 R S
2 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
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9 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
11 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
12 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
16 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
17 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
19 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
25 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
29 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
30 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
32 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
33 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
36 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
39 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
41 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
42 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
56 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
59 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
60 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
64 EURL ENT-12.6 Ciprofloxacin CIP 8 4 R S
11 EURL ENT-12.6 Quinupristin/dalfopristin (Synercid) SYN 4 8 S R
33 EURL ENT-12.6 Quinupristin/dalfopristin (Synercid) SYN 4 8 S R
40 EURL ENT-12.6 Quinupristin/dalfopristin (Synercid) SYN 4 8 S R
20 EURL ENT-12.6 Tigecycline TGC 0,5 0,12 R S
41 EURL ENT-12.6 Tigecycline TGC 0,5 0,12 R S
17 EURL ENT-12.7 Tigecycline TGC 0,5 0,12 R S
34 EURL ENT-12.7 Tigecycline TGC 0,5 0,12 R S
20 EURL ENT-12.8 Daptomycin DAP 8 4 R S
42 EURL ENT-12.8 Daptomycin DAP 8 4 R S
64 EURL ENT-12.8 Linezolid LZD 16 2 R S
17 EURL ENT-12.8 Tigecycline TGC 0,5 0,12 R S
20 EURL ENT-12.8 Tigecycline TGC 0,5 0,12 R S
22 EURL ENT-12.8 Tigecycline TGC 0,5 0,12 R S
26 EURL ENT-12.8 Tigecycline TGC 0,5 0,12 R S
34 EURL ENT-12.8 Tigecycline TGC 1 0,12 R S
45 EURL ENT-12.8 Tigecycline TGC 0,5 0,12 R S
Excluded from the report (>25% deviations)
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Staphylococcus aureus  ‐ deviations
Lab code Strain ID Antimicrobial Read_value Exp_value Interp. Exp_interp.
4 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
9 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
11 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
12 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
17 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
20 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
22 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
23 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
26 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
29 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
31 EURL ST‐12.1 Ciprofloxacin CIP > 1.0 1 R S
39 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
45 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
59 EURL ST‐12.1 Ciprofloxacin CIP = 2.0 1 R S
31 EURL ST‐12.1 Penicillin PEN > 8.0 > 2 R
11 EURL ST‐12.1 Sulfamethoxazole SMX = 128.0 512 S R
40 EURL ST‐12.2 Fusidic acid FUS <= 2.0 <= 0.5 R S
40 EURL ST‐12.2 Mupirocin MUP = 1.0 <= 0.5 R S
31 EURL ST‐12.2 Penicillin PEN <= 0.12 <= 0.12 S
36 EURL ST‐12.2 Sulfamethoxazole SMX > 512 <= 64.0 R S
45 EURL ST‐12.2 Sulfamethoxazole SMX > 512 <= 64.0 R S
34 EURL ST‐12.3 Cefoxitin FOX = 2.0 8 S R
22 EURL ST‐12.3 Ciprofloxacin CIP = 8.0 8 S R
2 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
4 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
9 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
11 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
12 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
17 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
20 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
21 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
22 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
23 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
25 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
26 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
29 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 4.0 1 R S
30 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
36 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
40 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
45 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
56 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
59 EURL ST‐12.3 Quinupristin/dalfopristin (Synercid) SYN = 2.0 1 R S
40 EURL ST‐12.3 Sulfamethoxazole SMX = 512.0 <= 64 R S
45 EURL ST‐12.3 Sulfamethoxazole SMX > 512.0 <= 64 R S
25 EURL ST‐12.4 Clindamycin CLN = 1.0 1 S R
34 EURL ST‐12.4 Clindamycin CLN = 0.25 1 S R
31 EURL ST‐12.4 Penicillin PEN > 8.0 > 2 R
56 EURL ST‐12.4 Quinupristin/dalfopristin (Synercid) SYN = 1.0 2 S R
45 EURL ST‐12.4 Sulfamethoxazole SMX > 512.0 <= 64 R S
39 EURL ST‐12.4 Tetracycline TET = 2.0 <= 0.5 R S
39 EURL ST‐12.5 Cefoxitin FOX = 8.0 4 R S
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39 EURL ST‐12.5 Ciprofloxacin CIP = 8.0 = 0.5 R S
17 EURL ST‐12.5 Clindamycin CLN <= 0.12 > 4 S R
34 EURL ST‐12.5 Clindamycin CLN <= 0.12 > 4 S R
56 EURL ST‐12.5 Clindamycin CLN = 0.25 > 4 S R
17 EURL ST‐12.5 Erythromycin ERY <= 0.25 > 8 S R
34 EURL ST‐12.5 Erythromycin ERY <= 0.25 > 8 S R
56 EURL ST‐12.5 Erythromycin ERY = 0.5 > 8 S R
4 EURL ST‐12.5 Kanamycin KAN = 16.0 8 R S
26 EURL ST‐12.5 Kanamycin KAN = 16.0 8 R S
17 EURL ST‐12.5 Quinupristin/dalfopristin (Synercid) SYN = 1.0 2 S R
30 EURL ST‐12.5 Quinupristin/dalfopristin (Synercid) SYN = 1.0 2 S R
34 EURL ST‐12.5 Quinupristin/dalfopristin (Synercid) SYN = 1.0 2 S R
56 EURL ST‐12.5 Quinupristin/dalfopristin (Synercid) SYN = 1.0 2 S R
17 EURL ST‐12.5 Tiamulin TIA = 2.0 4 S R
39 EURL ST‐12.5 Trimethoprim TMP > 32.0 <= 2 R S
39 EURL ST‐12.6 Cefoxitin FOX > 4.0 2 R S
39 EURL ST‐12.6 Chloramphenicol CHL > 16.0 8 R S
39 EURL ST‐12.6 Ciprofloxacin CIP = 4.0 <= 0.25 R S
39 EURL ST‐12.6 Gentamicin GEN = 4.0 <= 1 R S
12 EURL ST‐12.6 Sulfamethoxazole SMX = 256.0 <= 64 R S
45 EURL ST‐12.6 Sulfamethoxazole SMX > 512.0 <= 64 R S
45 EURL ST‐12.7 Sulfamethoxazole SMX > 512.0 <= 64 R S
39 EURL ST‐12.7 Tetracycline TET > 16.0 <= 0.5 R S
22 EURL ST‐12.7 Trimethoprim TMP = 4.0 <= 2 R S
39 EURL ST‐12.7 Trimethoprim TMP = 4.0 <= 2 R S
45 EURL ST‐12.7 Trimethoprim TMP = 4.0 <= 2 R S
34 EURL ST‐12.8 Cefoxitin FOX = 2.0 8 S R
39 EURL ST‐12.8 Cefoxitin FOX = 4.0 8 S R
40 EURL ST‐12.8 Fusidic acid FUS = 2.0 <= 0.5 R S
Excluded from the report (>25% deviations)
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Escherichia coli  ‐ deviations
Lab code Strain ID Antimicrobial Read_value Exp_value Interp. Exp_interp.
61 EURL EC‐12.2 Cefotaxime FOT 1 <= 0.25 R S
61 EURL EC‐12.2 Ceftazidime TAZ 8 <= 0.5 R S
61 EURL EC‐12.2 Chloramphenicol CHL 32 <= 8 R S
61 EURL EC‐12.2 Sulfamethoxazole SMX 128 16 R S
26 EURL EC‐12.3 Azithromycin AZI 16 64 S R
61 EURL EC‐12.3 Azithromycin AZI 32 64 S R
45 EURL EC‐12.3 Cefoxitin FOX 16 8 R S
40 EURL EC‐12.3 Chloramphenicol CHL <= 8 > 128 S R
61 EURL EC‐12.4 Cefotaxime FOT 0.5 <= 0.25 R S
4 EURL EC‐12.4 Tigecycline TGC 1 2 S R
23 EURL EC‐12.4 Tigecycline TGC = 0.5 2 S R
26 EURL EC‐12.4 Tigecycline TGC = 0.5 2 S R
61 EURL EC‐12.4 Tigecycline TGC 1 2 S R
6 EURL EC‐12.6 Cefoxitin FOX 16 8 R S
22 EURL EC‐12.6 Cefoxitin FOX 16 8 R S
26 EURL EC‐12.6 Cefoxitin FOX 16 8 R S
33 EURL EC‐12.6 Cefoxitin FOX 16 8 R S
39 EURL EC‐12.6 Cefoxitin FOX 16 8 R S
22 EURL EC‐12.6 Ceftazidime TAZ = 0.5 = 0.5 R S
45 EURL EC‐12.6 Ceftazidime TAZ 1 <= 0.5 R S
23 EURL EC‐12.6 Colistin COL 2 4 S R
33 EURL EC‐12.6 Colistin COL 2 4 S R
40 EURL EC‐12.6 Colistin COL 2 4 S R
45 EURL EC‐12.6 Colistin COL 2 4 S R
4 EURL EC‐12.6 Imipenem IMI 0.25 2 S R
11 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
19 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
20 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
21 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
26 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
34 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
40 EURL EC‐12.6 Imipenem IMI = 0.25 2 S R
42 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
56 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
59 EURL EC‐12.6 Imipenem IMI = 0.5 2 S R
4 EURL EC‐12.6 Meropenem MERO 0.12 = 0.5 S R
11 EURL EC‐12.6 Meropenem MERO = 0.12 = 0.5 S R
11 EURL EC‐12.6 Meropenem MERO = 0.12 = 0.5 S R
26 EURL EC‐12.6 Meropenem MERO = 0.12 = 0.5 S R
26 EURL EC‐12.6 Meropenem MERO = 0.12 = 0.5 S R
33 EURL EC‐12.6 Meropenem MERO = 0.12 = 0.5 S R
33 EURL EC‐12.6 Meropenem MERO = 0.12 = 0.5 S R
4 EURL EC‐12.7 Ciprofloxacin CIP 0.12 <= 0.015 R S
11 EURL EC‐12.7 Ertapenem ETP = 0.06 = 0.25 S R
2 EURL EC‐12.7 Gentamicin GEN 2 4 S R
4 EURL EC‐12.7 Gentamicin GEN 2 4 S R
6 EURL EC‐12.7 Gentamicin GEN 2 4 S R
9 EURL EC‐12.7 Gentamicin GEN 2 4 S R
12 EURL EC‐12.7 Gentamicin GEN 2 4 S R
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16 EURL EC‐12.7 Gentamicin GEN 2 4 S R
17 EURL EC‐12.7 Gentamicin GEN 4 4 S R
18 EURL EC‐12.7 Gentamicin GEN 2 4 S R
20 EURL EC‐12.7 Gentamicin GEN 2 4 S R
21 EURL EC‐12.7 Gentamicin GEN 2 4 S R
22 EURL EC‐12.7 Gentamicin GEN 2 4 S R
23 EURL EC‐12.7 Gentamicin GEN 2 4 S R
25 EURL EC‐12.7 Gentamicin GEN 2 4 S R
26 EURL EC‐12.7 Gentamicin GEN 2 4 S R
29 EURL EC‐12.7 Gentamicin GEN 2 4 S R
30 EURL EC‐12.7 Gentamicin GEN 2 4 S R
33 EURL EC‐12.7 Gentamicin GEN 2 4 S R
34 EURL EC‐12.7 Gentamicin GEN 2 4 S R
36 EURL EC‐12.7 Gentamicin GEN 2 4 S R
37 EURL EC‐12.7 Gentamicin GEN 2 4 S R
38 EURL EC‐12.7 Gentamicin GEN 2 4 S R
39 EURL EC‐12.7 Gentamicin GEN 2 4 S R
40 EURL EC‐12.7 Gentamicin GEN 2 4 S R
41 EURL EC‐12.7 Gentamicin GEN 2 4 S R
42 EURL EC‐12.7 Gentamicin GEN 2 4 S R
56 EURL EC‐12.7 Gentamicin GEN 2 4 S R
59 EURL EC‐12.7 Gentamicin GEN 2 4 S R
60 EURL EC‐12.7 Gentamicin GEN 2 4 S R
61 EURL EC‐12.7 Gentamicin GEN 2 4 S R
6 EURL EC‐12.7 Imipenem IMI 1 = 0.5 R S
12 EURL EC‐12.7 Imipenem IMI 1 = 0.5 R S
16 EURL EC‐12.7 Imipenem IMI = 0.5 = 0.5 R S
18 EURL EC‐12.7 Imipenem IMI 1 = 0.5 R S
19 EURL EC‐12.7 Imipenem IMI 1 = 0.5 R S
37 EURL EC‐12.7 Imipenem IMI 1 = 0.5 R S
41 EURL EC‐12.7 Imipenem IMI 1 = 0.5 R S
45 EURL EC‐12.7 Imipenem IMI 1 = 0.5 R S
60 EURL EC‐12.7 Imipenem IMI 1 = 0.5 R S
11 EURL EC‐12.7 Meropenem MERO = 0.12 = 0.25 S R
11 EURL EC‐12.7 Meropenem MERO = 0.12 = 0.25 S R
36 EURL EC‐12.7 Meropenem MERO = 0.12 = 0.25 S R
4 EURL EC‐12.7 Nalidixic acid NAL 64 <= 4 R S
18 EURL EC‐12.8 Azithromycin AZI 32 16 R S
45 EURL EC‐12.8 Azithromycin AZI 32 16 R S
6 EURL EC‐12.8 Cefoxitin FOX 16 8 R S
22 EURL EC‐12.8 Cefoxitin FOX 16 8 R S
40 EURL EC‐12.8 Ciprofloxacin CIP = 0.03 = 0.5 S R
42 EURL EC‐12.8 Sulfamethoxazole SMX > 1024 > 1024 S R
Excluded from the report (>25% deviations)
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